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ABSTRACT 
 
Poly(lactic-co-glycolic acid) (PLGA) microspheres are the most commonly used and 
commercially successful long-acting release depots (LARs) for delivery of peptide drugs. 
However, the approval of generic versions of these products are slow. Due to the complexity of 
the manufacturing process, concerns about bioequivalence of generic complex drug products 
have been raised by the U.S. Food and Drug Administration (FDA). In order to address these 
challenges, this work aims to help fill in the knowledge gap between: (a) raw materials and 
manufacturing parameters, (b) critical quality attributes, and (c) release performance and 
mechanisms for PLGA LARs encapsulating the model drug, leuprolide.   
The 1-month Lupron Depot® (LD) encapsulating water-soluble leuprolide in PLGA 
microspheres is the first injectable microsphere product launched in the US market. It is also a 
benchmark product upon which modern LAR products are often compared. Here, we describe 
the reverse engineering of the LD composition and important product attributes. Analyzed 
contents of the formulation and the determined PLGA characteristics matched well with the 
official values stated in the package insert and those found in the literature, respectively. The 
gelatin was identified as type B consistent with ~ 300 bloom. The 11-μm volume-median 
microspheres in the LD displayed very low content of residual moisture (< 0.5%) and methylene 
chloride (< 1 ppm). 
Composition-equivalent PLGA microsphere formulations to the LD were prepared as a 
function of raw material and manufacturing variables. The following variables were adjusted at 
xvii 
 
constant theoretical loading of 16.4% leuprolide: polymer supplier/ polymerization type, gelatin 
supplier/ bloom number, polymer concentration, 1st homogenization speed and time, volume of 
primary water phase, 2nd homogenization time, volume of secondary water phase and stirring 
rate. The encapsulation efficiency (EE) of gelatin (101 ± 1%) was observed to be higher than the 
EE of leuprolide (42%- 63%). Desirable conditions of polymer concentration, homogenization 
time and volume of secondary water phase were critical to achieving high EE of leuprolide. The 
prepared formulations displayed a larger median particle size, a more porous surface, and higher 
residual solvents compared to the LD. The microspheres prepared with the identified LD raw 
materials possessed the same glass transition temperature as the LD. The leuprolide release 
kinetics of the formulations were also highly similar to the LD exhibiting zero-order kinetics 
after a ~20% initial burst release and displayed the same release versus mass loss kinetics.  
The correlations between the process variables and emulsion size were established. The 
dimensionless Sauter mean diameter of primary emulsion droplet was proportional to the product 
of key dimensionless groups raised to appropriate power indices. A new dimensionless group 
(total surface energy/total energy input to fluid) was used to rationalize insertion of a 
proportionate time dependence in the scaling of the Sauter mean diameter. The increased 
viscosity of primary emulsion inhibited drug loss during microencapsulation while increased 
droplet size enhanced drug leakage to outer water phase. The Sauter mean diameter of secondary 
emulsion was also found proportional to the product of three dimensionless groups raised to 
appropriate power indices.  
In summary, the rigorous approach of reverse engineering, characterization of 
composition-equivalent formulations and understanding of emulsion formation in the 
microencapsulation process described in this thesis could be useful for further development of 
xviii 
 
generic or new peptide loaded PLGA microspheres, and for guiding decisions on the influence of 
process variables on product physicochemical attributes and release performance. 
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Chapter 1 Introduction 
 
 Poly(lactic-co-glycolic acid) (PLGA) formulations 
 Therapeutic proteins and peptides 
Therapeutic peptides and proteins become promising drug candidates in clinical treatment 
and the market is growing rapidly [1–3]. However, the development and approval of 
protein/peptide-based formulations has been limited by the poor bioavailability of peptide by 
noninvasive administration routes, instability of proteins during long-term storage and short half-
life of peptide in body circulation [4,5]. Efforts have been made to develop long-acting release 
(LAR) products to deliver peptide and protein continuously. The advantages of LAR products 
include increased stability and bioavailability, improved efficiency and enhanced patient 
compliance [4]. Most of the peptide formulations are delivered via invasive routes such as 
subcutaneous injections [4]. It is important and challenging to create safe and effective LAR 
formulations of peptides. 
 PLGA formulations for long-acting release  
Polymer based LAR formulations have been widely used in peptide/protein delivery 
systems. Commonly used polymers include poly(lactic-co-glycolic acid) (PLGA) and poly(lactic 
acid) (PLA) [6,7]. PLGA represents the “gold standard” of biodegradable polymers [7] due to its 
well-known biocompatible/biodegradable properties and commercial availability. PLGA is the 
copolymer of monomers lactic acid (LA) and glycolic acid (GA) (Figure 1-1). When PLGA is 
exposed to aqueous environment, the degradation of PLGA initiates and hydrolyzes polymer 
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chains to the original monomers, LA and GA, both of which are the byproducts of a variety of 
metabolic pathways in body [8]. Therefore, PLGA is considered as biocompatible material in 
vivo in terms of the minimal systemic toxic degradation products after administration [9]. It has 
been widely studied in controlled release formulations and applied in several U.S. Food and 
Drug Administration (FDA)-approved products [6,10,11].  
The polymers could be synthesized in two different ways: direct condensation (DC) of 
lactic and glycolic acids [12,13] and ring-opening (RO) polymerization of cyclic D,L-lactide and 
glycolide [14,15]. The DC method produces PLGA, usually with low molecular weight [13,16], 
from acid monomers and can be performed in the absence of catalyst [13]. Those polymers are 
expected to contain more randomly distributed LA-GA, LA-LA and GA-GA bonds. The RO 
method produces polymers under mild conditions in the presence of a variety of catalysts [15] 
and most of the commercially available polymers are made by the RO method to readily obtain 
products with high molecular weight [17,18]. PLGA may contain small levels of residual 
monomers which may influence the in vitro release profile [19].   
 
Figure 1-1. Chemical structures of monomers and PLGA. 
 Physicochemical properties and degradation of PLGA 
The key physicochemical properties of PLGA (molecular weight, LA/GA ratio, polymer 
end-group, etc.) affect the crystallinity, capacity of water-uptake, and mechanical strength of the 
polymer and further determine the degradation rate of polymer [8,20] and release kinetics of 
drug from controlled release formulation [21,22]. Degradation of PLGA is the hydrolysis of its 
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ester linkages [23] leading to the decline of molecular weight of polymer and mass loss from 
polymer matrix [24]. The PLGA with higher molecular weight loses its mechanical strength 
slower than the one with lower molecular weight [24]. Polydispersity index (PDI) of the polymer 
is calculated by the ratio of weight average molecular weight (Mw) to number average molecular 
weight (Mn) describing the width of the molecular weight distribution. PLGA formulations with 
a lower PDI have shown a reduced initial burst release and sustained drug release [25]. Due to 
the stereochemistry of the asymmetric α-carbon atom, lactic acid has D- and L- form, and thus 
there are three different forms of polymer: poly(L-lactic acid), poly(D-lactic acid) and poly(D,L-
lactic acid). All these forms may be applied in formulations [26] while D,L-polymers are 
preferable because of the amorphous property and the fact that it helps facilitate a homogenous 
distribution of drug within the polymer matrix [27] and maintain the morphology of the product 
during storage [1]. The molar ratio of LA/GA determines the crystallinity, hydrolytic capacity 
and hydrolysis rate of PLGA [27]. Glycolic acid is more hydrophilic than lactic acid, and thus a 
higher content of GA facilitates the water uptake and increases the degradation rate of the 
polymer up to 50% GA content after which the polymer becomes crystalline [8]. The end-group 
of PLGA could be either free carboxylic acid or end-capped with esters and the latter form 
decreases the degradation rate of PLGA [24,28]. Glass transition temperature (Tg) of PLGA is 
generally reported to be higher than 37 °C [23,29] indicating the polymer is in the glassy state 
with rigid structure in nature and physiological conditions until hydration of the polymer. The Tg 
is affected by the LA/GA ratio and Mw of the polymer and will be altered by the interaction 
between drug and polymer chains [1]. 
The cleavage of polymer chains takes place via erosion in two different ways: surface 
erosion and bulk erosion [30]. The rate of erosion and water penetration determine the type of 
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erosion [28]. If the rate of surface erosion is faster than the rate of water penetration, degradation 
proceeds from the surface of the polymer matrices and the interior polymers are assumed to be 
unchanged in dry state [7]. If the rate of water penetration is dominant, the cleavage will be 
initiated from the inside. The predominant form of erosion in PLGA is bulk erosion [28,31] 
because hydration is rapid and the hydrolysis of PLGA is faster than degradation products can 
leave the polymer [32].  
 Microencapsulation methods for peptides/proteins 
Until 2016, there were fifteen PLGA/PLA based drug products in the US market and 11 
of them were in microsphere dosage form [6]. The microsphere formulations are readily 
administered subcutaneously, intramuscularly or even orally [4,6,33]. Three methods mainly 
used to prepare PLGA microspheres include: double emulsion solvent evaporation, spray drying 
and phase separation-coacervation [7,11]. 
 Solvent evaporation 
Microencapsulation via solvent evaporation/extraction usually involves the formation of 
emulsions: single emulsion (e.g., oil-in-water (O/W) or oil-in-oil (O1/O2)), double emulsion 
(e.g., water-in-oil-in-water (W1/O/W2)) and solid-in-oil-in-water emulsion (S/O/W) [20,34]. 
Drug stability, solubility and solid-state properties determine the appropriate microencapsulation 
method to be used [20]. The critical steps for this method include formation of emulsion by two 
phases and solidification of microspheres by solvent removal [35].  
Double emulsion solvent evaporation has the following steps: formation of the primary 
emulsion and secondary emulsion, and removal of organic solvent via appropriate process. To 
form the primary emulsion, an aqueous solution of hydrophilic drug is added to a solution of 
polymer dissolved in the water-immiscible organic solvent (e.g. methylene chloride (DCM)), and 
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then the mixture is emulsified by homogenizer, vortex or ultrasonication. DCM is the most 
commonly used solvent due to the high solubility for a wide range of polymers, immiscibility 
with water, low boiling point (~40 °C), high volatility and high evaporation rate [36]. Other 
solvents that could also be used include chloroform, ethyl acetate, and DCM-acetone [34]. The 
organic solvent used in the manufacturing process will affect the morphology, encapsulation 
efficiency and release profile of the prepared microspheres. Bilati et al [37] compared the effect 
of emulsification instruments on the particle size of emulsion. Simple benchtop vortex 
instruments produce coarse emulsion droplets with poor quality while sonication sharply 
decreases the droplet size even within a short time [37]. But ultrasonication may cause decline of 
the polymer molecular weight and accelerate the release kinetics [20]. To form the complex 
double emulsion system, an aqueous emulsifier is added to the primary emulsion. Polyvinyl 
alcohol (PVA) is the commonly used emulsifier to prevent aggregation of droplets. Then the 
double emulsion is transferred to an aqueous medium and stirred for hours to evaporate the 
solvent and harden the microspheres. The formed microspheres are washed by water to remove 
the excessive PVA solution/unloaded drug, and then lyophilized for storage. This method is 
applicable to temperature sensitive drugs. By carefully controlling the complex procedures, this 
method may produce microspheres with efficient encapsulation of water soluble drug with high 
yield [1,11]. But encapsulation efficiency of hydrophilic drug may be limited [7] due to the 
water-soluble drug leakage from polymer phase to the outer water phase [38].  
 Spray drying 
Spray drying prepares microspheres by atomizing the emulsion into a stream of heated 
air, evaporating solvents and drying the particles in a short time. The first step is to create the 
atomization feed. It is usually a solution mixture of polymer and drug. For hydrophilic drugs, an 
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aqueous solution of drug is emulsified into the polymer dissolved organic solution to form a 
homogenous W/O emulsion. In some cases, temperature needs to be controlled to form a stable 
emulsion [39–41]. The second step consists of four phases [7,42,43]: a) atomization of liquid 
feed: the emulsion solution is transferred via a tubing at a certain speed into the atomizer. One of 
the most popular nozzles is two-fluid nozzle, which produces sprays by the disruptive action of a 
high velocity gas on a liquid stream at the exit of nozzle tip [44]; b) spray-air mixing: the sprayed 
droplets as well as the drying heated airflow enter the drying chamber. The mixing of air and 
atomized droplets allows for fast evaporation of the moisture [45]; c) solvent evaporation: the 
drying process involves heat transfer from the environment to the droplets and the mass transfer 
of vaporized moisture from droplets into the air [43]; d) dried particles separation: the particles 
will be collected by appropriate devices (e.g. cyclones).  The air and the powder enter the 
cyclone tangentially, and the air will follow a strong vortex motion, forming a spiral pattern 
movement. It is hard for the particles with larger size or higher density to follow the air stream, 
so they will strike the glass wall and fall down into the collection vessel due to the centrifugal 
forces [43]. The obtained powder may have the similar residual moisture content as the particles 
attained by the lyophilization. The one-step process makes spray drying method easy to be 
scaled-up [46]. And due to the heated airflow in the drying, the residual organic solvents in the 
spray dried microspheres is lower than that in the particles made by solvent evaporation even 
without further drying processes [47]. 
The disadvantage of spray drying is the exposure of the materials to high temperature, 
which may cause the instability for heat-sensitive compounds. The denaturation and degradation 
of protein is time dependent process [48]. Although the temperature of inlet air flow is high, the 
contact time between sprayed droplets and the hot air is limited. When the droplets and airflow 
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pass through the chambers in the same direction, the heat will be absorbed by the droplets and 
the surface temperature will increase. However, the maximum temperature of the final particles 
theoretically will not beyond the outlet air temperature (Tout) [48]. And in practice, the actual 
temperature of the products is about 15 to 25 °C lower than the Tout [49]. Therefore, it is feasible 
to apply the spray drying method to heat-sensitive agents, such as peptide and protein by careful 
temperature control. Other drawbacks of this method are unacceptable yield due to adhesion of 
the microspheres to the wall of the drying chamber and inability to atomize liquid with high 
viscosity. The example of marketed microspheres made by spray drying method is Suprecur® 
MP (long-acting biodegradable microparticles containing buserelin acetate). 
 Phase separation/Coacervation 
The coacervation was introduced to pharmaceutical filed in 1960s [7] as a 
microencapsulation method by organic phase separation. The coacervation process consists of 
[50]: a) formation of W/O emulsion: dispersing hydrophilic drug aqueous solution into a 
polymer dissolved oil phase (e.g. DCM) to form W/O emulsion via suitable methods (e.g. 
homogenization and sonication); b) formation of coacervate: gradually adding coacervate agent 
(e.g. silicone oil) to induce phase separation; the DCM is extracted into the silicone oil phase and 
embryonic microspheres begin to precipitate; c) hardening: transferring the mixture into an 
incompatible medium (e.g. heptane) to harden the soft microspheres by removing the solvents; 
and d) rinsing, drying and particle collection: excess solvents will be removed and washed off by 
water. The microspheres are sieved, dried under suitable conditions. The PLGA works as the 
wall or coating polymer and the coacervate agent is regarded as a phase inducer. The phase 
separation is induced due to the incompatibility between the polymer and the coacervation agent 
[51]. The wall polymer need to deposit on the surface of the drug preferentially to achieve good 
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encapsulation [7]. The biggest problem in coacervation process is the agglomeration of 
microspheres. Parameters, such as stirring rate and temperature, need to be optimized to address 
this problem [8]. The example of marketed microspheres made by coacervation is Bydureon® 
(exenatide extended-release for injectable suspension) [50]. 
 The effect of process variables on encapsulation by double emulsion solvent evaporation 
method 
The procedures of solvent evaporation method are complicated and costly. The 
parameters need to be delicately controlled to ensure successful encapsulation of the drug [7]. 
Studies have been reported on the effect of key parameters on the formulation properties and 
release performance. Polymer concentration is one of the most critical encapsulation variables 
influencing emulsion viscosity, particle size, encapsulation efficiency (EE), hardening kinetics, 
porosity, and initial burst release [52]. Increasing the polymer concentration raises the viscosity 
of the organic phase and the difficulty to break up polymer solution to small droplets [53], which 
in turn, increases the particle size, i.e., the volume mean diameter of the microspheres [54–56] 
even though the number weight diameter may not be affected [56]. Meanwhile, concentrated 
polymer solution shortens the evaporation time of organic solvent [57], limiting the drug escape 
from the polymer matrix, thus increasing the EE of the drug [53,55]. Li et al [58] found 
decreasing the polymer concentration also decreased the homogeneity of drug distribution in the 
microspheres. When the polymer concentration is low, water tends to accumulate easily within 
the polymer matrix and form internal water pockets, and the microspheres are dried with bigger 
pores and higher internal porosity [55,56,58]. Increased viscosity of the organic phase also 
facilitates the formation of a compact polymer core [59], or tends to increase particle size 
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[53,56], reducing surface/volume ratio [55] and then decrease drug initial burst and even slow 
down the whole release process [53]. 
W1/O phase volume ratio is expected to influence EE, particle size, porosity, and initial 
burst. When the volume of primary water phase (W1) is increased (i.e., a high W1/O ratio), it 
causes coalescence of water droplets and a less stable primary emulsion [37], and the particle 
size of microspheres is increased [53,55,60]. Such an effect may become negligible when the 
volume of W1 is over a certain value [56]. Increasing the water volume in the primary emulsion 
results in larger pores within the polymer network structure and decreases the bulk density 
[53,56]. When the W1/O ratio is dramatically decreased, a smooth surface is observed in 
microspheres [57]. Explanations for this observation are: increased amount of DCM in the 
emulsion decreases the removal rate of organic solvent, and prevents the formation of porous 
skin by re-dissolving the formed pores [53]; and less water decreases the viscosity of emulsion 
and causes a faster water diffusion from inside to the outer water phase, finally leading to fewer 
pores on the surface [57]. The effect of W1/O ratio on the EE of drug is complex. On the one 
hand, lower W1/O ratio enables a good emulsification during the formation of primary emulsion, 
and such a delicate interface minimizes the drug loss during the secondary emulsification [57] 
and increases the EE [55,56]. On the other hand, a higher W1/O ratio produces larger 
microspheres with a higher EE of drug [37,60]. Since a higher W1/O ratio leads to a higher 
internal porosity of the microspheres, a higher initial burst is often observed in those 
formulations [53,55,56]. 
The homogenization condition to prepare the primary emulsion (1st homogenization) is 
critical to control the size of primary emulsion droplets, microsphere size, inner pore size 
distribution, and initial burst. Homogeneous and fine primary emulsion droplets with good 
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quality will inhibit the coalescence during the second emulsification and drug loss to the outer 
water phase, and finally result in higher EE [37]. Mao et al [55] found increasing 1st 
homogenization speed decreased internal porosity and significantly increased EE of drug in 
microspheres with slightly increased particle size and lower initial burst.  
O/W2 phase volume ratio has been reported to affect particle size, solvent removal rate, 
porosity and release kinetics. When the second water phase volume is increased (low O/W2 
ratio), there is faster solvent removal rate due to the sink condition facilitating dissolving DCM 
in the outer aqueous phase [58]. In this case, solidification of the outer region of the 
microspheres occurs quickly and a thick skin layer is formed, which impedes the solvent transfer 
and the solvent can be trapped inside. A higher residual solvent level will be detected in the 
formulation in this case [58]. When the ratio is controlled in an appropriate range, increased 
outer water phase volume reduces the emulsification efficiency and leads to increased particle 
size [55,60]. But when the water phase volume is too low, coalescence may happen due to the 
high concentration of particles [54]. Mao et al [55] observed slightly decreased internal porosity 
and increased initial burst due to the increased surface porosity when the volume of outer water 
phase was increased.  
Stir rate has been shown to be a dominant factor that regulates the particle size [61]. 
When the mixing speed is increased, it will provide higher shear force [62] to break up the 
second emulsion into small droplets in the water phase and reduce the particle size of the 
microspheres [54,61,63]. The increased stirring rate may also give rise to more drug loss and low 
yield [63]. 
Peptide/protein concentration/theoretical loading is expected to have impact on porosity, 
EE and release kinetics. When the drug concentration is increased, the surface tension of the 
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primary emulsion is decreased, and bigger pores form in the microspheres. When theoretical 
drug loading is increased above a certain level, the EE might be reduced [61] due to the irregular 
shape and higher porosity of the microspheres prepared [64] and higher concentration gradient 
that causes more drug diffusion to outer water phase [55].  
Concentration of PVA solution mainly affects particle size. PVA is the commonly used 
emulsifier during microencapsulation to prevent coalescence of soft droplets by decreasing the 
interfacial tension and steric hindrance of incoming droplets [65]. When the concentration of 
PVA is increased or the molecular weight of PVA is increased, it prevents the separation of 
nascent emulsion droplets and increases the particle size of the microspheres [55,66,67], and 
leads to the aggregation or coalescence of particles [68]. The PVA is produced by hydrolysis of 
polyvinyl acetate and the hydrolysis degree relates to the amount of hydroxyl groups in the 
polymer [69]. Biehn and Ernsberger [65] found the PVA with high viscosity and low degree of 
hydrolysis is optimal to increase the stability of emulsion. 
 Initial burst release and release mechanism 
The drug release from PLGA microspheres follows a three-phase pattern including initial 
burst phase, lag-time and sustained release phase [70]. A phenomenon called “initial burst” is 
observed during the first 24 h of drug release, which is mainly due to the rapid release of loosely 
bounded drug from microspheres surface [70–72]. Wang et al [33] monitored the initial burst of 
octreotide loaded PLGA microspheres and provided other assumptions about the initial burst. 
The permeability of microspheres was found to continuously decrease during the first day of 
release and according to the level of permeability, three phases were proposed [33]: a) phase I 
(0-3 h): the initial release rate was high and sharply decreased after 30 min; the pore density at 
surface was increased; b) phase II (3-5.5 h): release rate increased gradually due to the increased 
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diffusion coefficient of peptide in the aqueous network; more drug was exposed to the pores and 
diffused from the pores inside microspheres; c) phase III (5.5-24 h): the surface porosity 
decreased; the release rate reduced gradually and approached zero at 24 h; a “skin” type structure 
was formed at the surface of the microspheres and the density was increased, which stopped the 
initial burst. The microspheres in this study was prepared by solvent evaporation method and the 
authors also indicated that the morphologies of microspheres prepared by other methods might 
be significantly different [33]. A lag time phase following the initial burst is often observed and 
it could be explained by the cessation of release after the closing of surface pores. During the lag 
period, water slowly penetrates the microspheres and the auto-catalysis takes place. Also the 
number of carboxylic acid end groups increases, lowering the pH in the microclimate [30,73]. 
These processes accelerate the erosion in polymer bulk, and then the drug release enters the third 
phase. The degradation products are accumulated in the microspheres. When the osmotic 
pressure inside the PLGA matrices reaches a threshold, the surface and bulk of the microspheres 
can be ruptured. The pore network allows for the release of monomers and oligomers [74]. Drug 
diffusion is also initiated and the peptide escapes from the microspheres via the aqueous 
channels [10]. Thus, the drug release rate is regulated by the rate of erosion and potentially rate 
of diffusion [10]. 
Multiple mechanisms are involved in the drug release from the microspheres including 
[75]: a) diffusion through pores: the water-soluble drugs could diffuse through the external pores 
and internal porous structures formed during the formation of microspheres and release to the 
external environment if the pore size is large enough and the pore network is continuous from 
drug phase to the surface of microspheres; polymer hydration will cause pore opening while 
polymer healing will close the pores; b) diffusion through polymer phase: polymer chains inside 
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of the microspheres forms a matrix barrier for drug release and the tortuosity will be reduced by 
the erosion and water uptake, creating less tortuous pathways for drug molecules [28]; c) osmotic 
pumping: water uptake upon exposure of microspheres to the release medium increases the 
osmotic pressure, creating new pores and driving the drug transport; d) erosion: 
degradation/erosion of polymer exposes the drug molecules to the surface of the microspheres 
[75,76]. Besides, the water absorption also causes a phenomenon called “swelling”, which 
indicates the increased volume of microspheres and increased mobility of polymer chains. 
Meanwhile, the Tg decreases, and the transition from glassy state to rubbery state takes place, 
which enhances the diffusion of drug within PLGA matrix [33,76].  
 Lupron Depot® 
Leuprolide acetate is a nonapeptide with the amino acid sequence: 5-oxo-Pro-His-Trp-
Ser-Tyr-D-Leu-Leu-Arg-Pro · acetate [77]. It is a synthetic analogue of gonadotrophin-releasing 
hormone (GnRH) (luteinizing hormone-releasing hormone (LH-RH)) and has higher affinity for 
GnRH receptors than the natural GnRH peptide [78]. So it is known as a super LH-RH agonist 
being able to inhibit the secretion of gonadotropin after continuous administration in therapeutics 
doses [2,78]. Leuprolide is usually used in the treatment for the hormone-dependent cancer or 
disorder, like breast and prostate cancer, endometriosis and uterine fibroids [78]. It has been a 
top LH-RH agonist holding a significant market share in the global peptide pharmaceutical 
market [79,80]. 
Leuprolide is orally inactive and usually administered subcutaneously or intramuscularly 
with a half-life of ~3-4 h [78,81]. Due to the inconvenience of frequent administration, efforts 
have been made on the development of PLGA/PLA based products for controlled release of 
leuprolide. Currently, such products available on US market include Lupron Depot, Lupron 
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Depot-PED, Lupron, Eligard and Lupaneta Pack [6]. Lupron Depot® (LD, leuprolide acetate for 
depot suspension) is a group of PLGA/PLA microsphere products loaded with leuprolide acetate 
for 1-, 3-, 4-, 6-month administration [82]. 
 Features of PLGA in the formulation 
From the patent and literature [83,84], we can assume the 1-month LD uses the PLGA 
produced by Wako Pure Chemical Industries, Ltd. (Tokyo, Japan) using direct condensation 
method. During the development of LD, the originator, Takeda Pharmaceutical Company Ltd. 
[54] analyzed the effect of some significant features of PLGA (e.g. Mw, LA/GA ratio, end-
capping and residual water-soluble acid number) on the microencapsulation of leuprolide. In the 
1-month depot formulation, PLGA (LA/GA ratio = 75/25) with average molecular weight of 
14000 was selected to achieve a desirable release performance and stability [1]. A contributing 
mechanism (which will be discussed later) of high EE of leuprolide in these microspheres is 
believed to be the interactions between the carboxylic acid of PLGA and amino acid residues of 
peptide [1]. The employment of acid-end group PLGA provides a large number of acidic 
residues that promotes the ionic interactions.  
 Excipients 
The 1-month LD microspheres encapsulate 10% of leuprolide and 1.7% of purified 
gelatin [77]. Gelatin was regarded as drug retaining substance [85] which may generate 
considerable viscosity and form a solid matrix [1]. The inventors claimed adding the gelatin 
significantly increased the EE of peptide [54]. However, it was later found that the cooling of the 
primary emulsion increased the viscosity of the emulsion, and the same high EE of peptide could 
be obtained even in the absence of gelatin [86]. So in describing the critical condition to achieve 
a high EE of leuprolide in microspheres the LD inventors stated: “unless there is an increase in 
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the inner phase viscosity, encapsulation efficiency will not be elevated even in the case of inner 
phase with higher concentration of gelatin” [54]. Gelatin was not used in 3,4 and 6- month 
Lupron Depot® [77] and removed from the 1-month product in Japan. D-Mannitol (15%) was 
added to the microspheres to prevent aggregation during lyophilization and storage [1]. 
 Manufacturing procedures for LD product 
Microencapsulation of leuprolide in LD was achieved by using a double emulsion solvent 
evaporation method invented and improved by Okada et al [54,85], Yamamoto et al [87], Kamei 
et al [88] and Igari et al [89]. Briefly, an aqueous solution containing leuprolide and gelatin was 
warmed to 60 to 70°C and emulsified in a DCM solution dissolving PLGA to form a W1/O 
emulsion, which was then cooled to 10 to 20 °C. This emulsion was emulsified in an aqueous 
PVA solution to form the W1/O/W2 emulsion. The secondary emulsion was stirred at room 
temperature to evaporate organic solvent. The solidified microspheres were dispersed in water 
and then centrifuged to wash off unloaded drug and PVA. D-mannitol powder was added to the 
recovered microspheres before lyophilization. The suspension was freeze-dried under reduced 
pressure to collect the microspheres powder [87–89]. 
 Encapsulation mechanisms for LD microspheres 
The basic amino acids (arginine and histidine) in the leuprolide interacted with the 
carboxylic acids of PLGA (pKa ~ 3.5) [90] during microencapsulation. The interaction has been 
proved by a chemical shift of arginyl and histidyl residues of leuprolide in the primary emulsion 
to lower magnetic field in NMR spectroscopy [91]. If the deprotonation of the polymer end 
group is disrupted by introducing acids to the water phase, the EE of peptide will be reduced due 
to the inhibition of the peptide-polymer interaction [1]. Okada et al [83] proposed a micelle-like 
structure for microspheres with leuprolide distributing throughout the polymer matrix and 
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forming a rigid drug core. The alkyl chains in the polymer formed a hydrophobic barrier that 
could prevent drug escape. 
The release of leuprolide from LD is mainly controlled by the degradation of polymer 
[83]. When the leuprolide loading increased from 0 to 8%, the corresponding Tg of the 
microspheres was also elevated [1,84], indicating increased leuprolide loading contributes to the 
ionic interaction. However, increasing water-soluble drug loading within the polymer phase will 
also give rise to more aqueous channels that limit high EE and accelerate initial burst [84]. Thus, 
the loading of leuprolide needs to be regulated to ensure a desirable EE and release behavior. For 
example, an appropriate loading of leuprolide in 3-month PLA microspheres was suggested to be 
12% [84].  
 Mechanistic understanding of microencapsulation 
As described in previous section (1.3), the manufacturing variables will affect the 
physicochemical properties and quality of emulsion, and subsequently regulate the attributes of 
microspheres. However, the current emulsion-based microencapsulation process is based on trial 
and error and has batch-to-batch variation and scale-up difficulties [92,93]. Quantitative 
experiments and correlations have been developed to improve the understanding of how the 
process variables influence the product attributes.  
The formation of emulsion is the dispersion of two immiscible liquid phases. The key 
manufacturing parameters in the droplet formation include: style, geometry and process variables 
of mixing device [62,94] and physicochemical properties of dispersed phase and continuous 
phase [95,96]. The common mixing devices are impeller/static mixer, rotor-stator mixer and 
ultrasonicator [62]. The high-shear rotor-stator mixers have been widely used in the 
emulsification process. The rotor-stator mixer has a stator with the rotor rotating at high speed 
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inside. The stators usually have holes or slots where the fluid flows through. The relationships 
between the geometry, rotor speed, and the energy dissipation have been studied [94,97–100]. 
The first step is to link the energy dissipation rate to geometry and rotor speed [94]. For the 
dimensional analysis, Atiemo-Obeng [101] indicated that the definition of power number (𝑃ை) 
and Reynolds number (𝑅𝑒) for rotor-stator mixer could be the same as those for conventional 
stirred tanks. The turbulent power could be described using the primary length scale, impeller 
(rotor) diameter. The power number (𝑃ை) is 
𝑃ை =
𝑃
𝜌𝜔ଷ𝐷ହ
 (1-1) 
where 𝑃 is the power, 𝜌 is the liquid density, 𝜔 is impeller speed and 𝐷 is rotor diameter. The 
Reynolds number is 
𝑅𝑒 =
𝜌𝜔𝐷ଶ
𝜇
=
𝜔𝐷ଶ
𝑣
 (1-2) 
where 𝜇 is the fluid dynamic viscosity. In the full turbulent regime (𝑅𝑒 is above ~104), the 𝑃ை is 
constant of Reynolds number [94] but dependent on the geometry of rotor-stator, and in the 
range of 2 to 6 [101]. When impeller type and thickness, and turbulent flow conditions are 
assumed to be constant, 𝑃ை becomes nearly constant [102]. The concept developed by 
Kolmogorov has been widely used to describe the turbulent eddies [95,103]. The Kolmogorov 
length scale (𝛿௄) is expressed as:  
𝛿௄ = (
𝑣ଷ
ε
)ଵ/ସ (1-3) 
where ε is the local energy dissipation rate per unit mass of fluid. For isotropic turbulence, ε 
could be expressed as the energy loss rate from mixer to the fluid divided by the mass of fluid 
(𝜌𝑉) [52,93]: 
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ε =
𝜌𝜔ଷ𝐷ହ𝑃ை
𝜌𝑉
=
𝜔ଷ𝐷ହ𝑃ை
𝑉
 (1-4) 
Then the 𝛿௄ is: 
𝛿௄ = (
𝑉𝜇ଷ
𝜔ଷ𝐷ହ𝜌ଷ𝑃ை
)ଵ/ସ (1-5) 
Droplet size (𝑑) and viscosity (𝜇) are the two key characteristic properties to describe the 
emulsion and these values have be reported to be correlated to [96,97,104–106]: continuous 
phase viscosity (𝜇௖) and density (𝜌௖), dispersed phase viscosity (𝜇ௗ) and density (𝜌ௗ), dispersed 
phase volume fraction (Φ), interfacial tension (σ), rotor speed (𝜔), and mixing time/pass times 
(𝑡). Sauter mean diameter (𝑑ଷ,ଶ) defined as the ratio of third and second moments of a particle 
size distribution, has been used to study the effect of processing variables on the physical 
properties of emulsion [95]. Based on the values of 𝛿௄, droplet size, and the viscosity of the 
solution, different correlations to predict mean particle size from dimensionless groups have 
been studied and summarized by Calabrese [92], Leng [107] and Hall et al [95,96]. Rotor stator 
mixers usually produce droplets with the diameter (𝑑) the order of 𝛿௄ and smaller (𝛿௄ > 𝑑) [92], 
and if the stress on droplet is inertial, the following correlation exists [92]: 
𝑑ଷ,ଶ
𝐷
∝ (𝑊𝑒𝑅𝑒)ି 
ଵ
ଷ (1-6) 
where 𝑊𝑒 is the Weber number and defined as  
𝑊𝑒 = 𝜌𝜔ଶ𝐷ଷ/σ (1-7) 
When 𝛿௄ >> 𝑑, the correlations is [92]: 
𝑑ଷ,ଶ
𝐷
∝ (𝑊𝑒𝑅𝑒ସ)ି 
ଵ
଻ (1-8) 
If the droplets are broken by turbulent viscous stress, the relationship becomes [92]: 
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𝑑ଷ,ଶ
𝐷
∝ (𝑊𝑒ିଵ𝑅𝑒ଵ/ଶ) (1-9) 
Hall et al [95] found that the rotor speed (𝜔) and dispersed phase viscosity (𝜇ௗ) have 
more significant influence on the droplet size compared to the other parameters (e.g., Φ and ఓ೏
ఓ೎
 ) 
in an O/W emulsion prepared by in-line Silverson rotor-stator mixer. But when the 𝜇ௗ is above a 
certain value, the droplet size is independent of the dispersed phase viscosity [95,108]. Pai [105] 
indicated that in the O/W system, the viscosity ratio (ఓ೏
ఓ೎
) is usually high and deformation of 
droplets might not happen. Studies on the kinetics of droplet size during emulsification reported 
that the mean droplet size (𝑑) is exponentially correlated with ultrasonication time [106,109,110] 
and a general equation to describe size decays as a function of time (𝑡) is expressed as [106]: 
𝑑 = 𝑦଴ + 𝐴𝑒
 (௧ି௧బ)ఛ  (1-10) 
where 𝑦଴ is the saturation diameter, 𝜏 is the characteristic decay time, 𝑡଴ is the first time when a 
mean droplet size is detected, and the corresponding size value is (𝑦଴ + 𝐴). Before time 𝑡଴, it is 
assumed that two immiscible phases are in a heterogeneous system [106].  
The viscosity of a suspension of solid spheres could be predicted by Einstein equation 
[111,112]: 
𝜇
𝜇௖
= 1 + 2.5Φ (1-11) 
Taylor [113] derived an equation for emulsions with small concentration of dispersed phase: 
𝜇
𝜇௖
= 1 + (
𝜇௖ + 2.5𝜇ௗ
𝜇௖ + 𝜇ௗ
)Φ (1-12) 
Krieger and Dougherty [114] proposed an alternative empirical model for a high concentration of 
dispersed phase and when the Φ is low: 
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𝜇
𝜇௖
= 1 + (
𝜇ௗ
𝜇௖
− 1)Φ (1-13) 
 Research Scope and Impact 
PLGA LARs have gained commercial success and some of them could be good 
candidates serving as reference drugs for the generic product filing. However, complex and 
aseptic unit processes and specialized instrument could cause difficulties to scale up with low 
yields, and ultimately a high cost of goods. Changes in raw materials and manufacturing 
conditions may cause different attributes and release performance resulting in batch failure 
and/or changes to safety and efficacy. Studies are needed to fill in the knowledge gap between 
raw materials/manufacturing parameters and products attributes/release 
performance/mechanisms in composition-equivalent formulations. The resulting approach is 
expected to facilitate the development of new and generic peptide loaded microsphere products. 
 Thesis Overview 
The preceding introduction discusses the difficulties that might impede the development 
of generic peptide loaded PLGA products and the key parameters involved in the solvent 
evaporation method. The one-month Lupron Depot® was selected as model drug product since it 
is a benchmark product upon which modern long-acting release products are often compared. 
Despite expiration of patent coverage, no generic product for the LD has been approved in the 
USA. The overall goal of this project is to understand how raw materials and variables in 
manufacturing processes will affect the attributes, release performance and mechanisms of 
composition-equivalent formulations relative to the Lupron Depot. Ultimately, the results 
described here could help on the development of new and generic peptide loaded microsphere 
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products and may offer an aid in FDA regulation development for generic drug of LARs in the 
future. This thesis consists of 5 chapters describing key concepts to address these concerns. 
Chapter 2 describes reverse engineering of the 1-month Lupron Depot®. Analytical 
methods for analyzing the components of the LD, including its diluent, were developed, and the 
specific composition was identified and quantified. The results are consistent with the values 
reported in the drug label and literature. The gelatin was identified as Type B with Bloom 300. 
Attributes including particle size distribution, residual water and solvent levels, Tg, and in vitro 
release demonstrate the unique features of this product.   
Chapter 3 focus on the development of composition-equivalent PLGA formulations for 1-
month controlled release leuprolide as a function of manufacturing variables/raw materials. The 
effect of those variables on product attributes and release performance in vitro were studied. This 
section shows the composition, Tg, and in vitro release kinetics of the microspheres loaded with 
leuprolide can be largely replicated on the bench scale. The loading efficiency of leuprolide is 
lower than that of gelatin. Changes in initial burst release often mirrored changes in drug 
loading/encapsulation efficiency. Changing manufacturing variables centered at a standard 
formulation did not strongly affect release behavior in vitro. 
Chapter 4 develops a mechanistic understanding of microencapsulation. Particularly, this 
section seeks to understand how to use the input manufacturing variables to predict 
characteristics of emulsion by mathematical correlations. Nondimensional correlations were 
established based on the literature, Buckingham Π theory and creation of a new dimensionless 
group (surface energy/energy input to fluid) to derive relationships between emulsion droplet 
size and manufacturing variables. The correlations between the process variables with emulsion 
viscosity and droplet size were identified and further linked to the results of EE in Chapter 3. 
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The conclusions of this research and potential future applications are discussed 
in Chapter 5. Chapter 2 was published in AAPS Journal in 2018. Chapters 3 and 4 are in 
preparation for publication. 
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Chapter 2 Reverse engineering the 1-month Lupron Depot®1 
 
 Abstract 
The 1-month Lupron Depot® (LD) encapsulating water-soluble leuprolide in poly(lactic-
co-glycolic acid) (PLGA) microspheres is a benchmark product upon which modern long-acting 
release products are often compared. Despite expiration of patent coverage, no generic product 
for the LD has been approved in the USA, likely due to the complexity of components and 
manufacturing processes involved in the product. Here, we describe the reverse engineering of 
the LD composition and important product attributes. Specific attributes analyzed for 
microspheres were as follows: leuprolide content by three methods; gelatin content, type, and 
molecular weight distribution; PLGA content, lactic acid/glycolic acid ratio, and molecular 
weight distribution; mannitol content; in vitro drug release; residual solvent and moisture 
content; particle size distribution and morphology; and glass transition temperature. For the 
diluent, composition, viscosity, and specific gravity were analyzed. Analyzed contents of the 
formulation and the determined PLGA characteristics matched well with the official numbers 
stated in the package insert and those found in literature, respectively. The gelatin was identified 
as type B consistent with ~ 300 bloom. The 11-μm volume-median microspheres in the LD 
slowly released the drug in vitro in a zero-order manner after ~ 23% initial burst release. Very 
                                                 
1 Adapted by permission from Springer Customer Service Centre GmbH: Springer Nature The AAPS Journal, 
Reverse Engineering the 1-Month Lupron Depot®, Jia Zhou, Keiji Hirota, Rose Ackermann, Jennifer Walker, Yan 
Wang, Stephanie Choi, Anna Schwendeman and Steven P. Schwendeman, 2018 
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low content of residual moisture (< 0.5%) and methylene chloride (< 1 ppm) in the product 
indicates in-water drying is capable of removing solvents to extremely low levels during 
manufacturing. The rigorous approach of reverse engineering described here may be useful for 
development of generic leuprolide-PLGA microspheres as well as other new and generic PLGA 
microsphere formulations. 
 Introduction 
The 1-month Lupron Depot® (LD) is a poly(lactic-co-glycolic acid) (PLGA) microsphere 
product, which encapsulates and slowly releases leuprolide acetate, to reduce injection frequency 
relative to daily injections of soluble peptide for treatment of hormone-sensitive prostate cancer, 
breast cancer, endometriosis, and uterine fibroids [1,2]. Since its launch in the USA in 1989, the 
LD has become a benchmark product with which modern long-acting release (LAR) PLGA 
products are often compared. Annual market sales of LD in the USA was $580 million in 2014 
[115], making it an attractive candidate for generic competition. Despite expiration of patent 
coverage, no generic product for the LD has been approved in the USA. Three- and six-month 
LD formulations are also commercialized, which are also of interest for generic development.  
For injectable PLA/PLGA-based drug products, the proposed generic product should be 
qualitatively (Q1) and quantitatively (Q2) the same as the reference listed drug (RLD) to be 
considered for approval in an Abbreviated New Drug Application (ANDA) according to the 
505(j) pathway [116]. The extensive list of ingredients of LD is expected to pose challenges to 
generic product development [1,77]. Referring to publications of LD and the package insert [77], 
the 7.5 mg LD for 1-month administration formulation is prefilled in a dual-chamber syringe for 
better usability. The powder filled in the front chamber (chamber 1) contains microspheres 
loaded with leuprolide and gelatin (7.5 mg leuprolide acetate, 1.3 mg gelatin and 66.2 mg 
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PLGA) and 13.2 mg D-mannitol. The injection diluent filled in the second chamber (chamber 2) 
is composed of 5 mg carboxymethylcellulose sodium (Na-CMC), 50 mg mannitol, 1 mg 
polysorbate 80, water for injection (USP), and glacial acetic acid to control pH (USP) [77]. 
Before administration, the microspheres will be mixed with the diluent thoroughly until a 
homogeneous suspension forms [77].  
As an initial step in the generic drug development, the relevant analytical methods need 
to be established to determine the composition of the RLD. The characteristic properties of 
active and inactive ingredients are also of interest for the potential use in the selection of 
manufacturing materials for generic drug product development. For example, comprehensive 
characterization of PLGA is required in the generic application of polymer-based products [54]. 
The key properties of PLGA, including lactic acid/glycolic acid (LA/GA) ratio, molecular weight 
distribution and polymer end-group identity, all could affect the release mechanism and release 
rate of the drug from the microspheres. In addition, the PLGA synthesis method and presence or 
absence of specific catalyst could also potentially affect product performance. During the 
manufacturing process of microspheres, the PLGA polymer could potentially degrade resulting 
in changes in the formulated product, which may cause failure in an equivalence test. Another 
complex ingredient in the case of LD is gelatin. Gelatin was originally added to the leuprolide 
solution to increase encapsulation efficiency in the manufacturing of microspheres [54]. Later it 
was found that increasing the viscosity of the primary emulsion by cooling was the key step to 
achieve high encapsulation efficiency of leuprolide in the microspheres [1,86]. Gelatin is a 
mixture of proteins and peptides derived from collagen in animal tissues and bones. Gelatins are 
derived most commonly from bovine and porcine sources as type A or B, according to acid or 
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base hydrolysis, and possess a gel strength indicated by bloom number [117]. However, the 
specific gelatin product used in the LD formulation is not disclosed to the best of our knowledge.  
We describe the reverse engineering of the 1-month LD injection system to (a) determine 
the identity and quantity of specific components of this formulation, (b) characterize key aspects 
of the formulation critical to performance of the product, and (c) establish chemical assays that 
are useful to accomplish the above. By improving our understanding of the LD, the barrier to 
increasing the number of PLGA products can be reduced, especially to those pursuing generic 
PLGA products for leuprolide.   
 Materials and Methods 
 Chemicals and Reagents 
The 7.5 mg leuprolide dose for one-month administration Lupron Depot® (LD, AbbVie 
Inc., North Chicago, IL, USA) was employed for reverse engineering the product composition. 
The LD products were purchased from the pharmacy department at the University of Michigan 
Health System. Leuprolide acetate with purity more than 98% by high-performance liquid 
chromatography (HPLC) analysis was purchased from Soho-Yiming Pharmaceuticals Co. Ltd. 
(Shanghai, China). This leuprolide acetate was detected by UV absorbance at 280 nm of 
wavelength on ultra-performance liquid chromatography (UPLC) and confirmed to be within 
100.55 ± 2.16 % (mean ± SEM, n=3) of the USP standard (USP 36 NF 31; catalog number: 
1358503; lot: I0M442) in the range of 0-600 g/mL. Gelatin products used in this paper include: 
type B gelatin derived from porcine skin with bloom number 300 (beMatrixTM Low Endotoxin 
Gelatin LS-W) and type B gelatin derived from bovine bone with bloom number 250 were 
purchased from Nitta Gelatin Inc. (Osaka, Japan); type A gelatin derived from porcine skin with 
bloom number 300 and type B gelatin derived from bovine skin with bloom numbers 75 and 225 
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were purchased from Sigma-Aldrich (St. Louis, MO, USA). Hereafter, the gelatins are 
designated by “company name; type; bloom number”. The AccQ•Tag Chemistry kit was 
purchased from Waters (Waters Corporation, Milford, MA, USA). All solvents used were HPLC 
grade and were purchased from Fisher Scientific. Wako 7515 PLGA polymer (catalog No. 823-
11966) was purchased from Wako Pure Chemical Industries, Ltd. (Tokyo, Japan). 
 Determination of leuprolide acetate loading 
Two extraction methods were employed to determine the leuprolide content in the LD 
formulations. A single extraction method (Method 1) was published by LD originator, Takeda 
Pharmaceutical Company Ltd [21,54] where methylene chloride (DCM) was used to dissolve 
PLGA microspheres and 1/30 M sodium phosphate buffer at pH 6.0 was used to extract 
leuprolide acetate into the aqueous phase. Approximately 5 mg of formulation was weighed 
accurately and 10 mL of DCM and 20 mL of phosphate buffer (pH 6.0) was added. The 
supernatant of the aqueous phase was obtained after mixing the solution vigorously for 5 min 
and subsequent centrifugation (2000 g, 5 min) at room temperature.  
In Method 2, 5 mg of the LD formulation was dissolved in 750 L DCM and then 
leuprolide acetate was extracted with 750 L of 50 mM sodium acetate buffer at pH 4.0 
[118,119]. In order to extract leuprolide from the organic phase, this extraction process was 
repeated for 5 times [118] and then with 50 mM sodium acetate buffer pH 4.0 containing 1 M 
sodium chloride (11 total extractions) [119]. Between each extraction, the supernatant was 
collected by centrifugation at 6000 g for 4 min at room temperature.  
In both methods, the content of leuprolide acetate in the aqueous phase was determined 
by UPLC. The UPLC system consisted of an Acquity Quaternary Solvent Manager, Sample 
Manager-FTN, Column Manager and TUV Detector (Waters, Milford, MA, USA). The 
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separation of leuprolide was carried out with an Acquity UPLC BEH C18 column (1.7 m, 2.1 x 
100 mm, Waters, Milford, MA, USA) and a gradient elution of acetonitrile with 0.1% TFA 
(solvent A) and water with 0.1% TFA (solvent B) at a flow rate of 0.5 mL/min as follows: 0 min 
(25% A), 2 min (35% A), and 2.5 min (25% A), followed by 1 min recovery with initial 
conditions. The concentration of leuprolide was detected by UV absorbance at 280 nm of 
wavelength and its peak appeared around a retention time of 2.4 min. Three batches of LD with 
different lot numbers were used and the experiment was performed in triplicate. 
Amino acid analysis was used as the third method (Method 3) to determine the content of 
leuprolide acetate in LD. Leuprolide contains 9 amino acids and tyrosine (Tyr) and histidine 
(His) are the specific amino acids that do not exist in the gelatin [1,117]. Histidine was used to 
determine the content of leuprolide. About 25 mg of LD formulations or 5 mg of leuprolide 
acetate were weighed into hydrolysis tubes and 1.0 mL of 6 N constant boiling HCl (Fisher 
Chemical, Fair Lawn, NJ, USA) was added. The tubes were purged under nitrogen, sealed under 
light vacuum, and incubated at 110 °C for 24 h. After incubation, the solution was frozen with 
liquid nitrogen and lyophilized under vacuum at room temperature. Then, 400 L of 20 mM HCl 
was added into each tube to reconstitute the samples. Standard solutions of leuprolide acetate 
were prepared by dilution of the hydrolyzed leuprolide samples. Derivatization and analysis were 
performed by using Waters AccQ•Tag Chemistry kit. Briefly, hydrolyzed amino acids were 
derivatized using the borate buffer (<5% sodium tetraborate in water) with the Waters 
AccQFluor reagent (6-aminoquinolyl-N-hydroxysuccinimidyl carbamate). Norleucine was 
added to the samples during the derivatization and used as the internal standard. The derivatized 
samples were separated by reverse phase UPLC using a C18 column (AccQTag Ultra C18, 1.7 
m (Millipore Corporation, Milford, MA, USA)) and a gradient elution of solvent A (5% 
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solution of Waters AccQTag Eluent A concentrate (19 wt% sodium acetate, 6-7 wt% 
phosphoric acid and 1-2% wt% triethylamine)) and solvent B (2% formic acid in acetonitrile 
solution) at a flow rate of 0.5 mL/min as follows: 0 min (99.9% A), 1 min (98.5% A), 11.5 min 
(78% A), 13.5 min (40% A) and 15 min (99.9% A), followed by a 2 min recovery with initial 
conditions. The urea derivatives yielded during the derivatization were detected by fluorescence 
(excitation-emission, 250-395 nm). Three batches of LD with different lot numbers were used 
and the experiment was performed in triplicate.  
 Characterization of the gelatin in the LD formulation 
2.3.3.1 Determination of gelatin type 
Ion exchange chromatography was employed to differentiate the pI difference between 
type A and B gelatin in order to identify the gelatin type in the LD formulation. To extract 
gelatin from the LD formulation, the formulation powder was first suspended in ice-cold water to 
dissolve and remove the D-mannitol from the sample. Ice-cold water was used to inhibit 
degradation of PLGA. The suspended microspheres were collected using a nylon membrane 
filter with 0.20-m pores under vacuum and then washed with another 5 mL of ddH2O to rinse 
off mannitol bound to the microspheres. Then, the microspheres were transferred into a pre-
weighed 2-mL tube and dried at room temperature under vacuum until the weight of the sample 
remained constant. The dried mannitol-free microspheres (i.e., microspheres without mannitol) 
were dissolved in 5 mL of DCM and 10 mL of ddH2O was added. The mixture was heated to 60 
C and mixed well to extract gelatin and leuprolide into the aqueous phase. After centrifugation 
at 2000 g for 5 min at 40 C with slow brake, 8 mL of the aqueous phase was collected and 
replaced with the same volume of ddH2O. The extraction was repeated one more time and then 
the extract was collected after lyophilization of the aqueous solution. 
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Since the extract contained leuprolide as well as gelatin, leuprolide was removed by using 
a centrifugal filter unit (Amicon Ultra-15, 10 KDa cutoff, EMD Millipore Corp., Darmstadt, 
Germany) to avoid the interference in the ion exchange chromatography. Briefly, the extract was 
reconstituted with 15 mL of 6 M acetic acid and transferred into the molecular cut-off filter 
device, followed by centrifugation at 5000 g for 40 min at 30 °C. Then, 12 mL of 6 M acetic acid 
was added to the concentrated extract and the separation was repeated one more time. To remove 
the acetic acid in the purified samples, 11 mL of 10 mM sodium chloride solution pre-warmed at 
50 °C was added to the tube. The excessive solution was removed by centrifugation at 5000 g for 
30 min at 40 °C. This replacement process was performed twice. The purified gelatin extracts 
remaining on the upper layer of the filter tubes was collected after lyophilization. The dried 
extracts were reconstituted with ddH2O to make the final concentration of gelatin around 2 
mg/mL and heated to 60 °C for 15-20 min with several times of vortexing, and immediately 
applied to ion-exchange HPLC. Three batches of LD with different lot numbers were used. Type 
A and type B gelatins were dissolved in 6 M acetic acid, applied to a molecular cut-off filter 
device and processed in the same manner and used as reference samples. Concentrations of all 
gelatin samples were 2 mg/mL. 
The type of gelatin was analyzed by cation ion-exchange HPLC installed with a TSKgel 
SP-NPR column (Tosoh Bioscience LLC, King of Prussia, PA) and a gradient elution of solvent 
A (10 mM citric acid buffer at pH 3), solvent B (20 mM sodium phosphate buffer at pH 11.5) 
and solvent C (1 M NaCl) at a flow rate of 1 mL/min as follows: 0 min (74:26, A:B), 2 min 
(53:47, A:B), 5.5 min (24:76, A:B), 12 min (100% B) and 14.5 min (100% C) followed by 
recovery with initial conditions for 3 min; the column temperature was 50 °C. The wavelength of 
UV detection was 220 nm. After each run, acetic acid was used to wash the needle and ddH2O 
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was used to clean the residues on the column. A blank control was injected between samples to 
confirm there was no cross over contamination.  
2.3.3.2 Molecular weight (Mw) of gelatin  
The gel strength of gelatin is typically determined by a texture analyzer and described by 
bloom number. Briefly, 6.67% gelatin water solution is prepared in a specified 150 mL standard 
bloom jar. After chilling, the rigidity of the gel is measured as the force required to depress a 
standard probe with a diameter of 0.5 inch to a depth of 4 mm into the gel [117]. However, due 
to the limited quantity (1.3 mg) of gelatin in each syringe, preparing such a gelatin test solution 
is not a reasonable cost. As bloom number is related to molecular weight of gelatin [117], the 
distribution of gelatin molecular weight was studied instead of the bloom test, which requires 
extensive amount of sample to perform the assay. To determine the Mw, gelatin was extracted 
from the LD and purified as described in the gelatin typing section. Three batches of LD with 
different lot numbers were used. Three commercial gelatins with different bloom numbers (Nitta 
B 300, Nitta B 250 and Sigma B 75) were loaded in the microspheres as described below and 
extracted and purified in the same way. Extracted and purified gelatin was reconstituted with 
ddH2O at 2 mg/mL and 10 L of the samples were injected to UPLC installed with a TSKgel 
UP-SW3000 column (Tosoh Bioscience LLC, King of Prussia, PA, USA). The mobile phase was 
composed of 0.1 M potassium dihydrogen phosphate buffer and 0.1 M disodium monohydrogen 
phosphate buffer (1:1, v:v) and the flow rate was set to 0.2 mL/min. The column temperature 
was 30 °C and the sample temperature was 40 °C. The wavelength of UV detection was 230 nm. 
Protein standards (Gel Filtration Markers Kit, Sigma-Aldrich, St. Louis, MO, USA) were used as 
molecular weight markers. The standard mixture contained carbonic anhydrase, albumin, alcohol 
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dehydrogenase, β-amylase, apoferritin and thyroglobulin. The molecular weight of the standard 
mixture ranged from 29,000 to 700,000 Da. 
2.3.3.3 Preparation of PLGA microspheres for gelatin analysis 
Gelatin and leuprolide acetate were loaded into PLGA microspheres by solvent 
evaporation method. PLGA (600 mg) was dissolved in 1 mL DCM. Gelatin (10 mg) and 
leuprolide acetate (68 mg) were dissolved in 150 L ddH2O at 60 C. The water phase and the 
oil phase were mixed and then emulsified using a VirTis Tempest IQ2 homogenizer (SP 
Scientific Inc., Warminster, PA, USA) at speed 15000 rpm for 4 min to form a W1/O emulsion. 
The obtained W1/O emulsion was cooled to 18 C to increase the viscosity of the emulsion. 
Then, 4 mL aqueous 0.25% polyvinyl alcohol (PVA) (EG-40P) (Soarus L.L.C., Arlington 
Heights, IL, USA) solution was added to the W1/O emulsion and the mixture was homogenized 
at 12000 rpm for 4 min. After homogenization, a W1/O/W2 emulsion was obtained. The 
W1/O/W2 emulsion was transferred into 200 mL 0.25% PVA solution and stirred with an 
overhead stir-tester (Glas-Col G.K.H. stir-Tester and Model HST20 stirrer, Terre Haute, Indiana, 
USA) at 700 rpm for 3 h to evaporate the methylene chloride and solidify the oil phase. The 
suspensions were rinsed with at least 1 L of water to wash off the unencapsulated drug and PVA. 
The microspheres were passed through a 90-m opening sieve to remove the large microspheres 
and collected by centrifugation at 4000 rpm for 5 min. The microspheres were freeze-dried under 
vacuum for 48 h. 
2.3.3.4 Determination of content of gelatin by amino acid analysis 
Amino acid analysis was performed in the same way as described in the Determination of 
Leuprolide Acetate Loading section. Standard solutions of gelatin were prepared by dilution of 
the hydrolyzed Nitta B 300 gelatin samples. Gelatin has several specific amino acids such as 
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alanine (Ala), asparagine and aspartic acid (Asx), hydroxylproline (OH-Pro) and valine (Val), 
which do not exist in the nonapeptide sequence of leuprolide [1,117]. The second abundant 
amino acid in the gelatin, alanine, was used to determine the gelatin content in the LD 
formulation. Poor reproducibility was found when using glycine, the most abundant amino acid 
in the gelatin, likely because of poor peak separation. Three batches of LD with different lot 
numbers were used and the experiment was performed in triplicate.  
 Characterization of the polymer in the LD formulation 
2.3.4.1 Determination of the PLGA weight average molecular weight (Mw), number average 
molecular weight (Mn), and polydispersity index (PDI) 
As the cryoprotectant in the LD, D-mannitol is insoluble in tetrahydrofuran (THF) and it 
was removed as described in gelatin typing section. Then, mannitol-free LD microspheres were 
dissolved in dehydrated THF at 4 mg/mL. As the presence of moisture/water can induce 
degradation of the polymer, THF was dehydrated by 3Å molecular sieves (Sigma-Aldrich, St. 
Louis, MO, USA). The samples were subjected to gel-permeation chromatography (GPC) 
installed with two styragel columns (HR 1 and HR 5E columns, Waters, Milford, MA, USA) and 
a refractive index detector (2414 refractive index detector, Waters, Milford, MA, USA). 
Polystyrene standards with Mw ranging from 1,000 Da to 50,000 Da were dissolved in the 
dehydrated THF. Mw, Mn and PDI of PLGA were calculated by Breeze software (Waters, 
Milford, MA, USA). 
2.3.4.2 Quantitative NMR analysis to determine PLGA content and lactic acid (LA) to glycolic 
acid (GA) ratio 
Quantitative 1H NMR (qNMR) (Varian, Inc., Palo Alto, CA, USA) was used to determine 
the ratio of lactic acid and glycolic acid as well as the content of PLGA by using dimethyl 
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terephthalate (DMT) as an internal standard [120]. The mannitol in the LD formulations was 
removed as described in gelatin typing section. The mannitol-free LD microspheres were 
dissolved in CDCl3 at 15-20 mg/mL with DMT at 1.0-2.0 mg/mL and subjected to NMR 
analysis. From the area of the peaks, the masses of LA and GA in PLGA were determined using 
the following equation [120], 
              𝑀௦ = 𝑀ூௌ ∙
𝑀𝑤௦
𝑀𝑤ூௌ
∙
𝑛𝐻ூௌ
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 (2-1) 
where “s” designates LA or GA in polymer and “IS” represents the internal standard; Ms 
and MIS are the masses, Mws and MwIS are the molecular weights in g/mol; Ps and PIS are the 
purities; nHs and nHIS are the numbers of protons that contribute to the peak signals used for 
integration; and As and AIS are the peak areas for the selected peaks [120]. It is noted that Ps was 
set at 100% because the purity of PLGA to manufacture LD was undisclosed.  
2.3.4.3 Determination of acid number of PLGA 
The number of free carboxylic acid end group in PLGA was determined by organic phase 
titration [31]. Approximately 10 mg of LD was dissolved in 5 mL of dehydrated 
acetone/tetrahydrofuran (1:1, v:v) mixture. Phenolphthalein methanol solution (0.1 wt%) was 
added as an indicator. The solution was immediately titrated with 0.01 M methanolic potassium 
hydroxide to a stable pink end point. The acid number of PLGA was calculated using the 
following equation:  
𝐴𝑐𝑖𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 [𝑚𝑔 𝐾𝑂𝐻/ 𝑔 𝑃𝐿𝐺𝐴]
=  
(𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 [𝑚𝐿]) × (𝑁௄ைு) × (𝑀𝑤௄ைு)
(𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑃𝐿𝐺𝐴 [𝑔])
 
(2-2) 
 
 
 Characterization of the diluent 
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2.3.5.1 Determination of pH of diluent in the LD formulation 
The pH of diluent was determined by a pH meter (430 pH Meter, Corning, Inc. Corning, 
NY, USA) equipped with a microelectrode (MI-410, Microelectrodes, Inc., Bedford, NH, USA). 
The pH meter was calibrated using standard solutions at pHs 4 and 7 at room temperature.  
2.3.5.2 Determination of water content of diluent  
The diluent is supposed to contain 5 mg (0.5%) Na-CMC, 50 mg (5%) D-mannitol, 1 mg 
(0.1%) polysorbate 80 in water for injection (1 mL injection diluent for a 7.5 mg dose of the 
drug), and glacial acetic acid (USP) to control pH [1,77]. The water content was estimated by the 
weight difference before and after drying of diluent. Approximately 300 L of the diluent was 
added to pre-weighed vials and the weight of diluent was recorded. After the diluent was dried at 
reduced pressure at 60 C for 48 h, the weight of sample was recorded. In order to confirm the 
weights of the samples remained constant and the water has been completely removed, the 
samples were further dried under the same conditions for an additional 2 h and the weight was 
measured again. This step was repeated for one more time to determine the final weight of the 
samples.  
2.3.5.3 Determination of D-mannitol content in the LD formulation and in diluent 
The content of D-mannitol was determined using a D-mannitol colorimetric assay kit 
(Sigma-Aldrich, St. Louis, MO, USA). D-mannitol was converted to D-fructose by mannitol 
dehydrogenase in the presence of NAD. This reaction produces NADH and the concentration of 
NADH could be determined by UV absorbance at 450 nm of wavelength. Approximately 1 mg 
of LD formulation was added to 2 mL tubes. The formulation was suspended in 1.5 mL of 
ddH2O and then centrifuged at 8000 g for 5 min. Then, 10 L of the supernatant was added to 
the 96-well plate using a pipette pre-calibrated by a balance. To determine the content of 
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mannitol in diluent, approximately 20 mg of the diluent was diluted 500 times with ddH2O and 
10 L of the samples were added to the 96-well plate by a pre-calibrated pipette. The assay 
buffer and reaction mixture solution were added according to the instructions in the assay kit. 
After the incubation at 37 C, the plate stood for another 30 min until the air bubbles 
disappeared. The concentration of mannitol was determined by UV absorbance at 450 nm of 
wavelength (SpectraMax M3, Molecular Devices, Sunnyvale, CA, USA).  
2.3.5.4 Determination of viscosity and specific gravity of diluent  
The viscosity of the diluent in LD was determined by an Anton-Paar rolling-ball 
viscometer Lovis 2000 M/ME, which measures the rolling time of a ball through liquid 
according to Hoeppler's falling ball principle [121]. The mimic diluent was prepared by adding 
Tween 80, Na-CMC (high viscosity or low viscosity, Sigma-Aldrich, St. Louis, MO, USA) and 
mannitol at the same ratio as the composition in diluent. 
Specific gravity was measured using a 1 mL pycnometer. The pycnometer was pre-
weighed and filled with the diluent in LD. Then the pycnometer was placed in a thermostatic 
bath with temperature controlled at 25 °C. After the temperature of the solution was equilibrated, 
excess volume of the solution expelled from the top of the pycnometer was absorbed with 
Kimwipes (Kimberly-Clark Professional, Roswell, GA, USA). The weight of the filled solution 
was recorded to determine the specific gravity using the density of water at 4 °C (density = 1 
g/mL). 
2.3.5.5 Determination of Tween 80 content in diluent 
To determine the content of Tween 80 in the diluent, bis-ANS (4,4’ -dianilino-1,1’ -
binaphthyl-5,5’ -disulfonic acid, di-potassium salt) was used as a fluorescence probe. This 
fluorescence probe is almost non-fluorescent initially, and the fluorescence increases when it 
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reacts with the hydrophobic group in Tween 80 [122]. Briefly, 50 L of diluent was mixed with 
950 L water and then 55 L of 1 mM bis-ANS solution was added. Then, the mixture was 
vortexed for 5 s and shaken at 220 rpm for 5 min, followed by no agitation to equilibrate for 25 
min. The stock standard solution of Tween 80 (Thermo Fisher Scientific Inc., Waltham, MA, 
USA) was prepared in ddH2O with the presence of Na-CMC and mannitol at the same ratio as 
the composition in LD diluent and it was further diluted to make serial standard solutions that 
fell within the range of 30-100 ppm. Two hundred L of the mixture was loaded to Costar 96-
well plates (black bottom polystyrene) and the concentration of Tween 80 was determined by 
fluorescence (excitation-emission, 380-500 nm) (SpectraMax M3, Molecular Devices, 
Sunnyvale, CA, USA).  
 Characterization of product attributes 
2.3.6.1 Particle size distribution 
The median diameter of the microspheres was determined using a Malvern Mastersizer 
2000 (Malvern Instruments Ltd., Worcestershire, UK). About 30-40 mg of LD formulation was 
suspended in 1 mL of diluent and vortexed vigorously before added to the instrument sample 
dispersion unit. Three measurements were performed per sample at a stirring speed of 2500 rpm 
and sampling time of 15 s.  
2.3.6.2 Surface morphology 
The surface morphology of microspheres was examined using a Hitachi S3200N 
scanning electron microscope (SEM) (Hitachi, Tokyo, Japan). The LD microspheres were ﬁxed 
on a brass stub using double-sided carbon adhesive tape and the samples were prepared 
electrically conductive by coating with a thin layer of gold for 120 s at 40 W under vacuum 
[123]. Images were taken at an excitation voltage of 10.0 kV.  
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2.3.6.3 Glass transition temperature  
The Tg of LD was determined with a modulated differential scanning calorimeter 
(mDSC) (TA Instruments, New Castle, DE, USA). LD microspheres (3-5 mg) were crimped in 
DSC aluminum pans. Temperatures were ramped between -20 °C and 90 °C at 3°/min. All 
samples were subjected to a heat/cool/heat cycle. The results were analyzed by using TA TRIOS 
software and Tg was taken as the midpoint of the reversing heat event. 
2.3.6.4 Residual moisture 
Residual water content in microspheres from the LD was determined by Karl Fischer 
(KF) titration. Eighty mg of LD was weighed into a vial and sealed with a septum cap. 
Anhydrous dimethyl sulfoxide (DMSO) was added to make the final concentration at 10 mg/ml 
and the sample was sonicated for 10 minutes before injected into the KF for titration. The 
moisture in the blank DMSO was also determined.  
2.3.6.5 Residual solvent 
Residual solvent (methylene chloride) in Lupron Depot® was determined by a Trace 1310 
gas chromatograph (GC) (Thermo Fisher Scientific Inc., Waltham, MA, USA). The LD 
microspheres were added into a glass vial containing anhydrous DMSO to make the final 
concentration at ~10 mg/ mL and the vial was sealed. The samples were applied to the GC by 
two different methods: headspace and liquid injections. For headspace injection, the GC 
conditions were as follows: nitrogen gas was used as the carrier solvent at a flow of 25 mL/min; 
air flow was 350 mL/min and hydrogen flow was 35 mL/min; the front detector temperature was 
240C and the front inlet pressure was a constant flow at 2 mL/min. Each sample was agitated 
for 20 min at 80C and 1 mL of the headspace sample was injected into the front inlet with the 
temperature of 140C, split flow of 40.0 ml/min, and a split ratio of 20. The GC column 
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temperature was initially set at 40C for 15 min, then increased at 10C/min to 240C and held at 
240C for 2 min. For liquid injection, the GC conditions were as follows: nitrogen gas was used 
as the carrier solvent at a flow of 33 mL/min; air flow was 450 mL/min and hydrogen flow was 
34 mL/min; the front detector temperature was 220C and the front inlet pressure was a constant 
flow at 12 mL/min. The injection volume was 1 L and the inlet operation was in splitless mode 
with temperature at 200C. The GC column temperature was initially set at 40C for 1 min, 
increased at 5C/min to 65C and then increased at 100C/min to 190C. A standard curve was 
prepared by adding methylene chloride to DMSO at 1, 10, 50, 100, 250, and 500 ppm.  
2.3.6.6 Release kinetics 
Drug release of microspheres was carried out using a sample-and-separate method in 
release medium PBST (phosphate buffered saline (PBS) + 0.02% Tween 80 + 0.02% NaN3, pH 
7.4). Microspheres (~10 mg) were suspended in 1 mL of medium and shaken mildly at 37 ºC. At 
each time point (1, 3, 7 days and weekly thereafter), the medium was completely collected after 
centrifugation at 8000 rpm for 5 min and replaced with fresh PBST buffer. The concentration of 
leuprolide in the supernatant was determined by UPLC as described in the section of 
determination of leuprolide acetate content.  
 Statistical Analysis  
Statistical analyses were carried out using GraphPad Prism 7.04 software. One sample t 
test was used to compare the measured values to the officially labeled numbers. The level of 
significance was established at the 95% confidence interval (α = 0.05). 
 Results and Discussion 
 Characterization of LD microspheres 
2.4.1.1 Leuprolide acetate content 
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Leuprolide acetate content in the one-month LD was determined by 3 different methods, 
as shown in Figure 2-1. Method 1, as performed by the originator of the LD, indicated 8.31 ± 
0.05 wt% (mean ± SEM, n=3) of leuprolide acetate in the LD. However, cationic leuprolide is 
capable of binding to negatively charged terminal chains of PLGA even in the DCM phase [118]. 
Note that the acetate counterion of leuprolide is less acidic than the end group of PLGA [124] 
and is therefore expected to deprotonate the polymer end group to some extent. Hence, method 2 
with multiple extractions of leuprolide acetate was performed, giving 8.95 ± 0.31 wt% (mean ± 
SEM, n=3) as the leuprolide acetate content. As expected, method 2 increased the recovery of 
leuprolide by 0.6 wt% more than method 1. In method 3, the leuprolide content was determined 
by the concentration of amino acid in the samples, which should not be affected by the 
interaction between the peptide and polymer that exists in the extraction method. The peak area 
ratios of histidine (retention time = 8.15 min) to the internal standard, norleucine (retention time 
=12.7 min), were used to determine the concentration of leuprolide based on the standard curve. 
The measured value, 8.89 ± 0.13 wt% (mean ± SEM, n=3), was slightly higher than the result in 
method 1 and comparable to that of method 2. All three methods provided reasonable measured 
values which were not significantly different (t test, p>0.05) from the officially reported value 
8.5 wt% in the package insert of LD [77]. The leuprolide acetate standard solutions used in this 
study were compared to the USP leuprolide acetate standard solutions on three different days and 
were confirmed to be within 100.5 ± 2.2 % (mean ± SEM, n=3) of the USP standard by UPLC in 
the concentration range of 0-600 g/mL. 
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Figure 2-1. Leuprolide content in LD formulations determined by two different extraction methods. All values present as mean ± 
SEM (n=3). The dash lines indicate the official LD loading. 
  
2.4.1.2 Gelatin type 
Figure 2-2 displays representative ionic exchange chromatographs of gelatin samples. 
Pure type A and B gelatin was differentiated based on their major peaks, which appeared at 
retention times around 13.5 min (Figure 2-2H) and 4.2 min (Figure 2-2F-G), respectively. The 
extracted gelatin from three different batches of LD shown in Figure 2-2B-D exhibited major 
peaks at roughly the same retention time as that of type B gelatin, which were far from that of 
type A gelatin. Therefore, the gelatin loaded in the LD was identified as type B.  
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Figure 2-2. Ion exchange chromatograms of (A) blank control, (B) LD extract lot #1, (C) LD extract lot #2, (D) LD extract lot #3, 
(E) type B gelatin with bloom number 300 from Nitta gelatin Inc., (F) type B gelatin from Sigma-Aldrich with bloom number 75, 
(G) type B gelatin from Sigma-Aldrich with bloom number 225 and (H) type A gelatin from Sigma-Aldrich with bloom number 
300. Note that negligible peaks are present in type A gelatin sample potentially due to the impurity in the product. 
2.4.1.3 Molecular weight of gelatin 
The representative chromatography of extracted gelatin from LD is shown in Figure 
2-3A. As the retention time of peaks are related to the molecular weight, the peaks were 
fractioned into 8 sections (Figure 2-3A&B) based on the molecular weight standards. The 
percentages of the area of peak were obtained to plot the Mw distributions of gelatin samples 
(Figure 2-3C). In Figure 2-3C, Nitta type B gelatins of bloom numbers 300 and 250, Sigma type 
B gelatins of bloom numbers 75 and 225 and Sigma type A gelatin 300 bloom were dissolved in 
acetic acid and collected after being applied to molecular cut-off filter device before UPLC 
analysis in the same way as the purification process of extracted gelatin from LD. Considering 
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the potential degradation of gelatin during dissolving, encapsulation and extraction, we dissolved 
and loaded various gelatins into the PLGA microspheres using polymer produced by Wako and 
leuprolide acetate according to the W/O/W method. Then we performed the extraction and 
purification process in the same way as described above for the LD. Three gelatins with 
relatively high, medium and low bloom numbers were studied in this experiment and the Mw 
distributions are designated as extracted Nitta B 300, extracted Nitta B 250 and extracted Sigma 
B 75 in Figure 3C. Compared to the gelatin samples without the encapsulation process, all of the 
extracted gelatins showed higher levels of lower Mw fractions indicating of gelatin hydrolysis 
during microspheres preparation. The extracted Nitta B 300 showed very similar Mw 
distributions to the extract from the LD (Figure 3C). To further confirm Nitta B 300 is 
comparable to the gelatin in LD in terms of their Mw distribution, we prepared three batches of 
microspheres loaded with Nitta B 300 gelatin and performed the extraction, purification and Mw 
analysis as described above. The Mw distributions of extracted Nitta B 300 gelatin were 
compared to the extracts from three different batches of LD in Figure 2-3D. From the results 
regarding peaks shape and Mw fractions, it is reasonable to conclude that the LD was 
encapsulated with high Mw gelatin (i.e., Bloom 300). Combined with the result from the gelatin 
typing section, the properties of Nitta B 300 gelatin matched the gelatin used in the LD. 
Furthermore, Nitta B 300 is manufactured with low endotoxin, suitable for injection and was 
used in publications [54] from the LD inventor. Therefore, Nitta B 300 gelatin was used as the 
reference gelatin in the measurement of gelatin content and identified as the probable source of 
gelatin in the LD. 
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Figure 2-3. GPC chromatograms of (A) extract from the LD and (B) extracted Nitta gelatin B after PLGA encapsulation; Mw 
distributions of different gelatin products (C); and comparison of the Mw distributions between extract from the LD and 
extracted Nitta B 300 (D) (the bars indicate mean ± SEM, n=3). * Extracted gelatin samples were taken after PLGA 
encapsulation. 
2.4.1.4 Gelatin content 
 The peak area ratios of alanine (retention time =10.05 min) to the internal standard 
(retention time =12.7 min) were used to determine the concentration of gelatin based on the 
standard curve. The average content of gelatin in the LD samples was determined as 1.55  0.08 
wt% (mean ± SEM, n=3) (Figure 2-4), which was not significantly different (t test, p>0.05) from 
the labeled content of 1.5% gelatin.  
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Figure 2-4. Gelatin content in the LD. All values represent mean  SEM (n=3). The dash line indicates the official LD loading. 
 
2.4.1.5 Molecular weight of PLGA 
PLGA is a biodegradable polymer by hydrolysis of ester bonds and the Mw of the PLGA 
is an important attribute to control the duration and kinetics of drug release [21]. Weight 
averaged molecular weight (Mw) and number averaged molecular weight (Mn) of LD was 
determined as approx. 13.0 kDa and 8.7 kDa, respectively with a PDI of 1.5 (Figure 2-5). The 
LD 7.5 mg is reported to be composed of PLGA with an LA/GA ratio, 75:25; Mw, 12.1 to 14 
kDa [21,22]; and a ratio of Mw to Mn (PDI) of 1.81 [21]. However, these characteristic numbers 
are related to the raw polymer before encapsulating leuprolide with gelatin by double emulsion 
solvent evaporation technique and Mw, Mn, and PDI could potentially be affected during the 
formulation process. Therefore, the results reflect the numbers of the PLGA in the finished 
product and were in reasonable ranges for Mw and Mn [21]. The PDI obtained in this study was 
slightly lower than the published one.  
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Figure 2-5. Characterization of PLGA in the LD formulations. The values of Mw, Mn and PDI represent mean  SEM (n=3). The 
dash lines indicate the official values. 
2.4.1.6 LA/GA ratio and content of PLGA 
LA/GA ratio is another attribute of PLGA to control the duration of release. The PLGA 
ester bonds (pairs of GA-GA, LA-LA and GA-LA or LA-GA) containing GA is less stable than 
the bonds with LA, and thus a higher content of glycolic acid facilitates the water uptake and 
increases the rate of degradation of the polymer [8]. As the release progress depends on the 
degradation of PLGA ester bonds, the composition of monomer changes over time of release, 
typically resulting in an increase in LA/GA  ratio [124].  
Figure 2-6 displays a representative NMR. The LA/GA ratio was determined from the 
proton signals generated by methyl (–CH3) and CH groups of GA and methylene (–CH2) groups 
of LA. The initial LA/GA ratio was found to be 74.3/25.7, which closely corresponded to the 
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expected values of 75/25 [1,22]. Additionally, the content of PLGA was determined by the sum 
of the masses of LA and GA calculated by equation (1). As summarized in Figure 2-5, it was 
found that the content of PLGA was 87.0 ± 0.3% (mean ± SEM, n=3), which is quite close to the 
officially reported PLGA mass 88.3% [77].  
 
Figure 2-6. 1H NMR spectrum of PLGA from the LD with internal standard dimethyl terephthalate (DMT). 
2.4.1.7 Acid number of PLGA 
The acid number represents the number of free carboxylic acid functionalities in the 
PLGA at the terminal of the polymer chain and is essential to evaluate whether end group is a 
carboxylic acid or an aliphatic ester. PLGA is insoluble in aqueous phase so titration was 
performed in acetone/tetrahydrofuran solution using methanolic KOH.  
The acid number of PLGA in a single lot of the LD 3.75 mg dose formulation was 
determined as 12.9 mg KOH/g PLGA. In the polymers with similar molecular weight, the 
polymer with a carboxylic acid end group always has higher acid number compared to the 
polymer with an ester-capped group [125]. Schrier and DeLuca [125] studied the acid numbers 
of different Resomer® polymer products (manufactured by Boehringer-Ingleheim (Ingleheim, 
Germany)) with and without ester end-capping, and showed that for the polymers with free acid 
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end and with molecular weight in the range of 8 – 12.5 kDa (RG 501H, 502H and 752H), the 
acid numbers were above 14 mg KOH/g PLGA while the ester end-capping forms had acid 
numbers below 2 mg KOH/g PLGA. The polymer Resomer® RG 752H has comparable 
molecular weight (Mw 13kDa) to the polymer used in LD and the acid number was reported as 
14.3 mg KOH/g PLGA [125]. The high value of the acid number obtained in this study indicates 
the PLGA is the acid end-group polymer instead of ester end-group polymer, consistent with the 
innovators’ publications and patents. 
2.4.1.8 D-mannitol content in LD formulation 
After encapsulation, D-mannitol was added to the microspheres to prevent aggregation 
during freeze drying process and to help resuspension of the microspheres before administration 
[1]. As shown in Figure 2-7, the measured content of D-mannitol mixed with microspheres was 
15.63 ± 0.43 wt% (mean  SEM, n=3), which was not significantly different (t test, p>0.05) from 
the expected number, 15 wt% [77]. 
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Figure 2-7. Contents of D-mannitol in the LD formulation and diluent, and water and tween 80 in the diluent. All values 
represent mean  SEM (n=3 for D-mannitol content in the formulation, water content and tween 80 content; n=4 for D-mannitol 
content in the diluent). The dash lines indicate the official LD compositions 
 Characterization of the diluent 
2.4.2.1 pH, water content and D-mannitol of diluent 
The diluent of a LD kit displayed a pH of 6.0-7.0. The content of water in the diluent was 
estimated as 94.55 ± 0.01 wt% (mean  SEM, n=3) (Figure 2-7) and the results showed close 
values relative to the official content 94.4 wt%. The content of D-mannitol in the LD diluent was 
determined as 4.42 ± 0.07 wt% (mean  SEM, n=3) (Figure 2-7). The value is close to but 
slightly lower than the official content of 5 wt%.  
2.4.2.2 Characterization of viscosity and specific gravity 
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It is considered that Na-CMC should be added to increase the viscosity of the diluent for 
maintaining the suspension of PLGA microspheres and for accurate injection. As characteristics 
of Na-CMC vary depending on Mw and viscosity, the diluent was initially subjected to 
microviscometry to identify the relative viscosity of Na-CMC. As a result, the viscosity of 
diluent was determined as 2.99  0.06 cP (mean  SEM, n=3) and the simulated diluent 
containing low viscosity Na-CMC and all the other ingredients at the same quantity as the 
commercial diluent showed a similar value of 3.31  0.03 cP (mean  SEM, n=3). The specific 
gravity of the LD diluent was determined to be 1.02. 
2.4.2.3 Tween 80 content 
The critical micellar concentration (c.m.c.) of Tween 80 is 13-15 ppm [126,127] and the 
formation of Tween 80 micelles may affect the interaction between the hydrophobic group in 
Tween 80 and the fluorescence probe used in the assay. The presence of Na-CMC and mannitol 
may also affect the formation of Tween 80 micelles and the generated fluorescence. Several 
studies were performed to avoid those influences in the measurement of Tween 80 content in 
LD. The results are not shown in this paper, but some key conclusions are summarized as below: 
1) Serial solutions of Na-CMC and mannitol were prepared in the absence of Tween 80 and 
showed negligible fluorescence; 2) the standard Tween 80 solutions with the presence of Na-
CMC and mannitol need to be prepared in the high concentration range (30-100 ppm) to achieve 
desirable linearity (R2=0.99). The injection diluent from the LD was diluted to the concentration 
that fell within this range to generate reliable results. The content of Tween 80 in the diluent was 
determined as 0.116 ± 0.003 wt% (mean  SEM, n=3) which was close to the official content of 
0.1 wt% (Figure 2-7).  
 Characterization of product attributes 
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The particle size distribution of LD (Figure 2-8) was narrow with a volume median 
diameter of 11.4  0.5 m (mean  SEM, n=3) (d (v, 0.5)). Ten percent of the volume 
distribution was below 3.8  0.2 m (mean  SEM, n=3) (d (v, 0.1)) and 90% of the volume 
distribution was below 30.0  0.6 m (mean  SEM, n=3) (d (v, 0.9)). These results were 
supported by the SEM micrographs. As seen in Figure 2-9, the LD formulations were spherical 
microspheres mixed with mannitol and the majority of the microspheres were < 20 m. The Tg of 
LD was measured as 48.6  0.1 °C (mean  SEM, n=3). Note that the presence of leuprolide has 
been reported to increase Tg of the microspheres as a result of the peptide-polymer interaction 
[1,118]. The water content of the LD was determined by Karl Fischer titration as 0.44  0.10% 
(mean  SEM, n=3), indicating careful drying of the product. Very surprisingly, the residual 
content of methylene chloride determined by two different GC methods was < 1 ppm. Clearly the 
in-water drying protocol is capable of achieving low levels of organic solvent in the final 
microspheres manufactured on a large scale. Lastly, as seen in Figure 2-10, the cumulative 
release of LD in PBST lasted for 7 weeks with a 22.8  0.4% initial burst on day one followed by 
a zero-order release after day three. The release curves after day one were fit using linear 
regression and the time to 50% release (t50) was calculated to be 12.3  0.2 days. Overall, these 
data are consistent with the existing literature [1,84] on the LD and a carefully formulated and 
manufactured product. 
52 
 
 
Figure 2-8. Particle size distribution of the LD microspheres. The columns indicate mean  SEM (n=3). 
 
Figure 2-9. SEM micrographs of LD formulation. 
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Figure 2-10. In vitro release of LD formulation. Data represent mean  SEM (n=5).  Error bars not plotted when smaller than 
symbols. 
Comparing and contrasting our data with those previously reported, mostly from the LD 
manufacturer, Takeda Chemical Industries, Ltd. (Osaka, Japan), we find excellent agreement and 
some new insights. The comparison between the published values and measured values are 
summarized in Table S 2-1. The determination of composition of chamber 1 provided reasonable 
measured values, which were not significantly different from the labeled values. The measured 
values of the composition of diluent was also close to the labeled values and the accuracy might 
be affected by the complexity of the diluent. The specific gelatin used in the formulation was 
identified in this report. The Mw of the polymer in the product was close to the reported Mw of 
raw polymer [1,21,22] indicating no significant degradation occurred during the manufacturing. 
The viscosity of the diluent was determined and was similar to the simulated diluent. The particle 
size distribution and SEM micrographs indicated the LD microspheres were fine and small 
particles, which matched the brief descriptions in the literature [1]. The Tg of the LD formulation 
showed a higher value compared to the raw polymer due to the interaction between peptide and 
polymer chains and relatively high drug loading (10%) [1,84]. The inventors stated the residual 
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DCM in the formulation was below 100 ppm [1] and our observation indicated this value was 
below 1 ppm. Ogawa et al [128] studied the release of leuprolide from PLGA by using rotating 
bottle method and phosphate buffer (pH 7) containing 0.05% Tween 80, and concluded the 
release kinetics followed zero-order release over 4 weeks by measuring peptide remaining in the 
microspheres. In this study, we used a sample-and-separate method and microspheres were 
incubated in PBST and shaken mildly. We observed a slightly faster initial release and a zero-
order release after day three. The release was more than 80% after day 35 and complete after day 
49. 
 Conclusions 
Analytical methods for analyzing the specific components of the 1-month Lupron 
Depot®, including its diluent, have been developed, and the ingredients have been identified and 
quantified. The results are consistent with the values reported in the drug label and literature, 
although we found the LD content by rigorous amino acid analysis and multiple extraction 
protocols slightly higher than listed in the drug label but not statistically significant. The most 
complex aspect of the analysis is the evaluation of gelatin in the LD, which may undergo 
hydrolysis during preparation of microspheres and extraction from drug product. The gelatin 
appears to be Type B with Bloom 300. Attributes including particle size distribution, residual 
water and solvent levels, Tg, and in vitro release demonstrate the unique features of this product. 
The analysis described here will be useful for further development of generic leuprolide 
microspheres and also could be applied for reverse engineering analysis of other PLGA-based 
long acting release products. 
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Table S 2-1. Summary and comparison of measured values to published values. 
 Ingredient Character variance 
Measured values (Mean 
SEM, n=3-5) Published values Reference(s) 
Chamber 1 
(microspheres 
mixed with 
mannitol) 
Leuprolide Content (%) 
8.31 ± 0.05 (Method 1) 
8.5 [1,77] 8.95 ± 0.31 (Method 2) 
8.89 ± 0.13 (Method 3) 
Purified gelatin 
Content (%) 1.55  0.08 1.47 [1,77] 
Type Type B - - 
Mw Bloom number 300 - - 
DL-lactic/glycolic acid 
copolymer 
L/G ratio 74.3/25.7 75/25 [1,54] 
Content (%) 86.5 ± 0.3 
75.06 
(88.27% in 
mannitol-free 
microspheres) 
[1,54,77] 
Mw (kDa) 13.04 ± 0.06 12-14 (raw polymer) [1,22,54] 
D-Mannitol Content (%) 15.6 ± 0.5 14.97 [1,77] 
Chamber 2 
(diluent) 
Carboxymethylcellulose 
sodium (Na CMC) Viscosity 
2.99 ± 0.06 mPa·s  
Low viscosity Na CMC - - 
D-Mannitol Content (%) 4.42 ± 0.07 5 [1,77] 
Polysorbate 80 Content (%) 0.116 ± 0.003 0.1 [1,77] 
Water Content (%) 94.55 ± 0.01 94.4 [1,77] 
Product attributes 
Particle size 11.4  0.5 m 20-30 m [1] 
Tg (°C) 
48.6 ± 0.1 
 
Tg (42-47 °C) of 
the microspheres 
increased as the 
[1,84] 
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(Leuprolide loading in 
mannitol-free microspheres is 
10%)  
peptide loading 
(0-8%) was 
increased. 
Residual 
solvent <1 ppm <100 ppm [1] 
Residual 
moisture 0.44  0.10% - - 
Cumulative release 
Methods Sample-and-separate method Rotating bottle method [128] 
Initial burst on 
day 1 (%) 22.8  0.4 - - 
Time to 50% 
release (t50) 
(days) 
12.3  0.2 16.6 [128] 
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Chapter 3 Effect of manufacturing variables and raw materials on the composition-equivalent 
formulations  
 
 Abstract 
 The 1-month Lupron Depot® (LD) is a poly(lactic-co-glycolic acid) (PLGA) 
microsphere product encapsulating 10% water-soluble leuprolide acetate. Despite expiration of 
patent coverage, no generic product for the LD has been approved in the US, likely due to the 
complexity of manufacturing processes involved in the LD formulation. Here we describe the 
development of composition-equivalent PLGA microsphere formulations to the LD as a function 
of raw material and manufacturing variables, and their influence on the product physicochemical 
attributes and release performance. The following variables were adjusted at constant theoretical 
loading of 16.4% leuprolide to achieve the desired 10% loading of peptide: polymer supplier/ 
polymerization type, gelatin supplier/ bloom number, polymer concentration, 1st homogenization 
speed and time, volume of primary water phase, 2nd homogenization time, volume of secondary 
water phase and stirring rate. The loading and encapsulation efficiency (EE) of leuprolide and 
gelatin were determined to identify composition-equivalent formulations within specification ± 
10% of the LD. Key properties of the formulations (e.g., morphology, particle size distribution, 
glass transition temperature (Tg), residual moisture and solvent, and porosity) were characterized 
to determine the effect of manufacturing variables on the product attributes. The EE of gelatin 
across all formulations prepared (101 ± 1%) was observed to be much higher than the EE of 
leuprolide (57 ± 1%). Desirable conditions of polymer concentration, 2nd homogenization time 
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and volume of 2nd water phase are key to achieving high EE of leuprolide although very high EE 
(>70%) was not achievable owing to the inability to emulsify primary emulsion with very high 
viscosity. The leuprolide release kinetics of the formulations were highly similar to the LD in a 
zero-order manner after ~20% initial burst release, indicating a critical role of the composition on 
peptide release in this case. The characterization of composition-equivalent formulations 
described here could be useful for further development of generic leuprolide PLGA 
microspheres, and for guiding decisions on the influence of process variables on product 
physicochemical attributes and release performance. 
 Introduction 
Polymer based long acting release (LAR) formulations have been widely used in 
peptide/protein delivery systems to increase bioavailability and reduce dosing frequency. 
Commonly used biodegradable and biocompatible polymers include poly(lactic-co-glycolic acid) 
(PLGA) and poly(lactic acid) (PLA) [6,7]. Several PLGA/PLA based microsphere products have 
gained commercial success and some of them could be good candidates serving as reference 
drugs for the generic product filing. However, the intricate preparation process may impede the 
development of PLGA-based generic drug products and increase the difficulties of regulation by 
U.S. Food and Drug Administration (FDA). Moreover, the composition-equivalent formulations 
developed under different manufacturing conditions may have different attributes and release 
performance, which may further influence the drug bioavailability, and in turn drug safety and 
efficacy. Despite of the investigation of effect of variables on some of the product properties, the 
relationship between raw materials/manufacturing parameters and products attributes/release 
performance from the scope of composition-equivalent formulations is not fully studied.  
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Lupron Depot® (LD) is a group of PLGA/PLA based LARs loaded with water-soluble 
nonapeptide, leuprolide acetate, for 1-, 3-, 4-, 6-month administration [82]. As a highly active 
luteinizing hormone-releasing hormone (LH-RH) agonist, leuprolide is able to inhibit the 
secretion of gonadotropin after continuous administration in therapeutics doses [2,78]. Hence 
leuprolide is used in the treatment for the hormone sensitive cancer or disorder, like breast and 
prostate cancer, and endometriosis [78]. It has been a top LH-RH agonist [79] holding a 
significant market share in the global peptide pharmaceutical market for decades [80]. Despite 
expiration of patent coverage, no generic product for the LD has been approved in the US. The 
one-month Lupron Depot® is the PLGA microspheres product launched on US market in 1989 
designed for monthly delivery of leuprolide. The LD consists of PLGA microspheres loaded with 
leuprolide and gelatin (7.5 mg leuprolide acetate, 1.3 mg gelatin and 66.2 mg PLGA), which are 
prepared by double emulsion solvent evaporation method. D-mannitol (13.2 mg) is added before 
lyophilization to prevent aggregation of microspheres [1,54]. Therefore, to mimic the LD 
product one must consider both the complexity of the manufacturing process and an extensive 
list of product ingredients [6]. 
In the previous work, we reverse engineered the LD to establish the relevant analytical 
methods and determine the raw materials, composition, characteristic properties and release 
kinetics of LD [129]. Based on the published literatures (including multiple patents) and our 
reverse engineering results, we identified the raw materials of inactive ingredients used in 
preparation of LD microspheres as Wako 7515 PLGA polymer produced by direct condensation 
(DC) method  [84,130] and beMatrixTM Low Endotoxin type B gelatin with bloom number 300 
produced by Nitta Gelatin Inc. First, those raw materials were used in preliminary pilot studies 
with the manufacturing variables regulated to establish a ‘standard’ condition that could produce 
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microspheres with desirable attributes and performance (e.g. equivalent loading as LD, high EE, 
spherical shape, suitable particle size, low initial burst release, and continuous long-term in vitro 
release). Then, a formulation table was established by creating multiple levels of the variables in 
the standard conditions and different formulations were generated by changing one variable a 
time from the standard condition. An equivalent PLGA synthesized by ring-opening (RO) 
polymerization of cyclic D,L-lactide and glycolide and various type B gelatins with different 
bloom numbers were employed to study the influence of raw materials on the leuprolide/PLGA 
formulations. Finally, sameness, key product attributes and release performance were studied to 
determine the causes of the possible differences between composition-equivalent formulations 
and reference product. 
We describe the development of composition-equivalent PLGA microsphere 
formulations to the 1-month LD. The characterization of composition-equivalent formulations 
described here could be useful for further development of generic or new LAR microsphere 
products, and for guiding decisions on the influence of manufacturing process variables on 
product attributes and release performance. 
 Materials and Methods 
 Chemicals and reagents 
Leuprolide acetate with purity more than 99% by high-performance liquid 
chromatography (HPLC) analysis was purchased from Bachem Americas Inc. (Torrance, CA, 
USA). This leuprolide acetate was detected by UV absorbance at 280 nm of wavelength on ultra-
performance liquid chromatography (UPLC) and confirmed to be within 101 ± 3 % (mean ± 
SEM, n=3) of the USP standard (USP 36 NF 31; catalog number: 1358503; lot: I0M442) in the 
range of 0-600 g/mL. Type B gelatin derived from porcine skin with bloom number 300 
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(beMatrixTM Low Endotoxin Gelatin LS-W) was purchased from Nitta Gelatin Inc. (Osaka, 
Japan). Type B gelatins derived from bovine skin with bloom numbers 75 and 225 were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Wako 7515 PLGA polymer was 
purchased from Wako Pure Chemical Industries, Ltd. (Tokyo, Japan). Resomer® 752H polymer 
was purchased from Sigma-Aldrich (St. Louis, MO, USA). Polyvinyl alcohol (PVA) 
(GOHSENOLTM EG-40P) was purchased from Soarus L.L.C. (Arlington Heights, IL, USA). The 
AccQ•Tag Chemistry kit was purchased from Waters (Waters Corporation, Milford, MA, USA). 
The 7.5 mg leuprolide dose for one-month administration Lupron Depot® (LD, AbbVie Inc., 
North Chicago, IL, USA) was purchased from the Hospital Pharmacy at University of Michigan 
Health System. All solvents used were HPLC grade and were purchased from Fisher Scientific.  
 Preparation of PLGA microspheres loaded with leuprolide 
Leuprolide acetate and gelatin were loaded into PLGA microspheres by solvent 
evaporation method. The raw materials used in the LD were identified in the previous reverse 
engineering studies [129] and published references by the originators [1,22,54]. Particularly, the 
polymer produced by Wako Pure Chemical Industries, Ltd. (Tokyo, Japan) by direct 
condensation method with average molecular weight of 14000 and LA/GA ratio of 75/25, and 
type B gelatin derived from porcine skin with bloom number 300 (beMatrixTM Low Endotoxin 
Gelatin LS-W, Nitta Gelatin Inc., Osaka, Japan) were employed in the procedure. Pilot studies 
were conducted to establish a ‘standard’ condition that could produce microspheres with 
desirable attributes and performance (e.g. equivalent loading as LD, high EE, spherical shape, 
suitable particle size, low initial burst release, continuous long-term release, etc.). The standard 
condition consisted of dissolving Wako PLGA (500 mg) in 1 mL methylene chloride (DCM). 
Gelatin (bloom number 300) (10.6 mg) and leuprolide acetate (100 mg) were dissolved in 120 
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L ddH2O at 60 C. The oil phase was transferred to the water phase and immediately vortexed 
for 20 s followed by emulsification using a VirTis Tempest IQ2 homogenizer (SP Scientific Inc., 
Warminster, PA, USA) at speed 10000 rpm for 2 min to form a W1/O emulsion. The obtained 
W1/O emulsion was cooled in an ice bath for 2 min to increase the viscosity of the primary 
emulsion. Two mL aqueous 0.25% PVA solution was mixed with the cooled primary emulsion 
by vortex for 20 s and homogenization at 15000 rpm for 30 s to form the secondary emulsion, 
i.e. a W1/O/W2 emulsion. The W1/O/W2 emulsion was transferred into 200 mL 0.25% PVA 
solution and stirred with an overhead stirrer (IKA Eurostar 60 Digital Constant-Speed Mixer, 
IKA Works, Inc., Staufen im Breisgau, Germany) at 750 rpm for 3 h to evaporate the DCM and 
solidify the polymer phase. The microsphere suspensions were passed through a 75-m opening 
sieve and washed with at least 1 L of water to rinse off the unencapsulated drug and PVA, and 
remove the large microspheres. The microspheres were collected by centrifugation at 4000 rpm 
for 7 min at 4 C and then mixed with a suitable amount of D-mannitol. The microspheres were 
freeze-dried under vacuum for 48 h.  
 Establishment of the formulation table 
To prepare a series of formulations with the same composition as the LD as a function of 
raw materials and manufacturing variables, a formulation table was created based on the standard 
condition. The selected manufacturing variables included polymer supplier/ polymerization type, 
gelatin supplier/ bloom number, polymer concentration, 1st homogenization speed and time, 
volume of primary water phase, 2nd homogenization time, volume of secondary water phase and 
stirring rate. The polymers synthesized by ring-opening (RO) polymerization of cyclic D,L-lactide 
and glycolide with the brand name Resomer® 752H was chosen as the second source of polymer. 
Another two type B gelatin products with lower bloom numbers from Sigma-Aldrich were used 
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in the corresponding formulations. For the other microencapsulation variables, the values in the 
standard condition served as medium level (level 2) and based on which low/ high levels (level 
1/ level 3) were created to form the formulation table (Table 3-1). Different formulations were 
generated by changing one variable a time from the standard condition with the constant 
theoretical loading of leuprolide at 16.4% and gelatin at 1.73%. The theoretical loading was 
calculated by: 
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑜𝑟 𝑔𝑒𝑙𝑎𝑡𝑖𝑛
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑃𝐿𝐺𝐴 + 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 + 𝑔𝑒𝑙𝑎𝑡𝑖𝑛
 × 100% (3-1) 
 
Table 3-1. Formulation table 
# Parameters Level 1 Level 2 
(Standard 
condition) 
Level 3 
Raw materials 
1 Polymer products/ polymerization type Resomer®/ 
RO 
Wako/ 
DC 
 
2 Gelatin suppliers/ bloom number Sigma/ 225 Nitta/ 300 Sigma/ 75 
Primary emulsion 
3 Concentration of PLGA in DCM 
(mg/mL) 
400 500 600 
4 W1/O phase volume ratio (v/v) 100 L/ 
1mL 
120 L/ 
1mL 
150 L/ 
1mL 
5 1st homogenization speed (rpm) 8000 10000 12000 
6 1st homogenization time (min) 1 2 3 
Secondary emulsion 
7 2nd homogenization time (s) 10 30 45 
8 O/W2 phase volume ratio (v/v) 1/1 1/2 1/4 
In-liquid drying conditions 
9 Stir rate (rpm) 450 750 900 
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 Determination of the PLGA weight average molecular weight (Mw) 
Raw polymer was dissolved in dehydrated tetrahydrofuran (THF) at 4 mg/mL. The 
samples were subjected to gel-permeation chromatography (GPC) installed with two styragel 
columns (HR 1 and HR 5E columns, Waters, Milford, MA, USA) and a refractive index detector 
(2414 refractive index detector, Waters, Milford, MA, USA). Polystyrene standards with Mw 
ranging from 1,000 Da to 50,000 Da were dissolved in the dehydrated THF. Mw of PLGA was 
calculated by Breeze software (Waters, Milford, MA, USA). 
 Determination of leuprolide acetate loading 
The loading of leuprolide acetate was determined by single extraction and amino acid 
analysis (AAA) [129]. In the single extraction method [21,54], 5 mg of formulation was 
dissolved in 1mL of DCM and then mixed with 2 mL of 1/30 M sodium phosphate buffer (pH 
6.0) by vortex for 5 min. The supernatant of the aqueous phase was obtained after centrifugation 
(4000 rpm, 5 min) at room temperature. The content of leuprolide acetate in the aqueous phase 
was determined by UPLC. The UPLC system consisted of an Acquity Quaternary Solvent 
Manager, Sample Manager-FTN, Column Manager and TUV Detector (Waters, Milford, MA, 
USA). The separation of leuprolide was carried out using an Acquity UPLC Peptide BEH C18 
column (1.7 m, 2.1 x 100 mm, Waters, Milford, MA, USA) and a gradient elution of 
acetonitrile with 0.1% TFA (solvent A) and water with 0.1% TFA (solvent B) at a flow rate of 
0.5 mL/min as follows: 0 min (25% A), 2 min (35% A), and 2.5 min (25% A), followed by 1 min 
recovery with initial conditions. The concentration of leuprolide was detected by UV absorbance 
at 215 nm of wavelength and its peak appeared around a retention time of 2.2 min. The loading 
of peptide and encapsulation efficiency (EE) were determined by the following: 
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𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑙𝑜𝑎𝑑𝑒𝑑
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠
 × 100% (3-2) 
𝐸𝐸 (%) =  
𝑙𝑒𝑢𝑝𝑟𝑜𝑙𝑖𝑑𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑙𝑜𝑎𝑑𝑖𝑛𝑔
 × 100% (3-3) 
Amino acid analysis was used as the second method to determine the content of 
leuprolide acetate in the microspheres [129]. Leuprolide contains 9 amino acids and tyrosine 
(Tyr) and histidine (His) are the specific amino acids that do not exist in the gelatin [1,117] and 
histidine content was used to determine the content of leuprolide as it provided reproducible 
results. About 25 mg of leuprolide/PLGA formulations or 5 mg of leuprolide acetate were 
weighed into hydrolysis tubes and 1.0 mL of 6 N constant boiling HCl (Fisher Chemical, Fair 
Lawn, NJ, USA) was added. The tubes were purged under nitrogen, sealed under light vacuum, 
and incubated at 110 °C for 24 h. After incubation, the solution was frozen with liquid nitrogen 
and lyophilized under vacuum at room temperature. Then, 400 L of 20 mM HCl was added into 
each tube to reconstitute the samples. Standard solutions of leuprolide acetate were prepared by 
dilution of the hydrolyzed leuprolide samples. Derivatization and analysis were performed by 
using Waters AccQ•Tag Chemistry kit. Briefly, hydrolyzed amino acids were derivatized using 
the borate buffer (< 5% sodium tetraborate in water) with the Waters AccQFluor reagent (6-
aminoquinolyl-N-hydroxysuccinimidyl carbamate). Norleucine was added to the samples during 
the derivatization and used as the internal standard. The derivatized samples were separated by 
reverse phase UPLC using a C18 column (AccQ·Tag Ultra C18, 1.7 m (Millipore Corporation, 
Milford, MA, USA)) and a gradient elution of solvent A (5% solution of Waters AccQ·Tag 
Eluent A concentrate in 19 wt% sodium acetate, 6-7 wt% phosphoric acid and 1-2% wt% 
triethylamine) and solvent B (2% formic acid in acetonitrile solution) at a flow rate of 0.5 
mL/min as follows: 0 min (99.9% A), 1 min (98.5% A), 11.5 min (78% A), 13.5 min (40% A) 
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and 15 min (99.9% A), followed by a 2 min recovery with initial conditions. The urea derivatives 
yielded during the derivatization were detected by fluorescence (excitation-emission, 250-395 
nm).  
 Determination of gelatin loading 
Amino acid analysis was performed in the same way as described in the previous section. 
Standard solutions of gelatin were prepared by dilution of the hydrolyzed Nitta B 300 gelatin 
samples. Gelatin has several specific amino acids such as alanine (Ala), asparagine and aspartic 
acid (Asx), hydroxylproline (OH-Pro) and valine (Val), which do not exist in the nonapeptide 
sequence of leuprolide [1,117]. The second abundant amino acid in the gelatin, alanine, was used 
to determine the gelatin content in the formulation [129]. The experiment was performed in 
triplicate. The EE of gelatin was calculated in the similar way as in equation (3-3). 
 Particle size distribution 
The median diameter of the microspheres was determined using a Malvern Mastersizer 
2000 (Malvern Instruments Ltd., Worcestershire, UK). About 30-40 mg of microspheres were 
suspended in 1 mL of water and vortexed vigorously before added to the instrument sample 
dispersion unit. Three measurements were performed per sample at a stirring speed of 2500 rpm 
and sampling time of 15 s.  
 Surface morphology 
The surface morphology of microspheres was examined using a TESCAN MIRA3 FEG 
scanning electron microscope (SEM) (Kohoutovice, Czech Republic). The microspheres were 
ﬁxed on a brass stub using double-sided carbon adhesive tape and the samples were prepared 
electrically conductive by coating with a thin layer of gold for 60 s at 18 mamp under vacuum 
[123]. Images were taken at an excitation voltage of 2 kV.  
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 Glass transition temperature  
The Tg of microspheres was determined with a modulated differential scanning 
calorimeter (mDSC) (TA Instruments, New Castle, DE, USA). Microspheres (3-5 mg) were 
crimped in DSC aluminum pans. Temperatures were ramped between -20 °C and 90 °C at 
3 °C/min. All samples were subjected to a heat/cool/heat cycle. The results were analyzed by 
using TA TRIOS software and Tg was taken as the midpoint of the reversing heat event. 
 Residual moisture 
Residual water content in the microspheres was determined by Karl Fischer (KF) 
titration. Eighty mg of formulation was weighed into a vial and sealed with a septum cap. 
Anhydrous dimethyl sulfoxide (DMSO) was added to make the final concentration at 10 mg/mL 
and the sample was sonicated for 10 minutes before injection into the KF for titration. The 
moisture in the blank DMSO was also determined.  
 Residual solvent 
Residual solvent (DCM) in the microspheres was determined by a Trace 1310 gas 
chromatograph (GC) (Thermo Fisher Scientific Inc., Waltham, MA, USA). The microspheres 
were added into a glass vial containing anhydrous DMSO to make the final concentration at ~10 
mg/ mL and the vial was sealed. The samples were applied to the GC by headspace injection. 
The GC conditions were as follows: nitrogen gas was used as the carrier solvent at a flow of 25 
mL/min; air flow was 350 mL/min and hydrogen flow was 35 mL/min; the front detector 
temperature was 240 C and the front inlet pressure was a constant flow at 2 mL/min. Each 
sample was agitated for 20 min at 80 C and 1 mL of the headspace sample was injected into the 
front inlet with the temperature of 140 C, split flow of 40.0 ml/min, and a split ratio of 20. The 
GC column temperature was initially set at 40C for 15 min, then increased at 10 C/min to 240 
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C and held at 240 C for 2 min. A standard curve was prepared by adding methylene chloride to 
DMSO at 1, 10, 50, 100, 250, and 500 ppm.  
 Porosity  
The porosity of microspheres was determined by mercury intrusion porosimetry 
(AutoPore V Series, Micromeritics, Norcross, GA, USA). About 80-150 mg of microspheres 
were weighed into 3 cc powder penetrometers to make the final used penetrometer stem volume 
in the range of 25-80%. Analysis was performed over low and high pressure ranging from 0.5 
psia - 61,000 psia with an equilibration of 10 s at each pressure. The curve of the cumulative 
intrusion volume per gram (mL/g) vs. filling pressure was reported. Interstitial void volume 
between the particles was filled before the mercury intrusion into the pores and subtracted from 
the total intrusion volume. The completion of inter-particle space filling was indicated by an 
abrupt change in filling rate on the intrusion volume curve [131] and the starting point of the 
corrected intrusion volume used for porosity calculation was determined at the inflection point. 
The porosity was calculated by the percentage of intrusion volume in the bulk volume. 
 Release kinetics of leuprolide from PLGA microspheres  
Drug release of microspheres was carried out using a sample-and-separate method in 
release medium PBST (phosphate buffered saline (PBS) + 0.02% Tween 80 + 0.02% NaN3, pH 
7.4). Microspheres (~10 mg) were suspended in 1 mL of medium and shaken mildly at 37 ºC. At 
each time point (1, 3, 7 days and weekly thereafter), the medium was completely collected after 
centrifugation at 8000 rpm for 5 min and replaced with fresh PBST buffer. The concentration of 
leuprolide in the supernatant was determined by UPLC as described in the section of determination 
of leuprolide acetate loading.  
 Kinetics of erosion 
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Microspheres (weight = 𝑊଴ ) were incubated in release medium at 37 °C under mild 
agitation. At each time point, the microspheres were washed by ddH2O and retrieved on 0.20 µm 
nylon filter paper under reduced pressure. The collected microspheres and filter paper were 
transferred into pre-weighed tubes and then dried under reduced pressure at room temperature for 
about 2 days. Dried microspheres were weighed (𝑊ଵ(𝑡)), and the mass loss was calculated by: 
𝑀𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 (%) =
𝑊଴ − 𝑊ଵ(𝑡)
𝑊଴
× 100% (3-4) 
 The mass loss after initial burst was plotted against the release after initial burst, which was 
calculated by: 
Release after initial burst(%) =
𝐴(𝑡) − 𝐴ଵ
𝐴௅ − 𝐴ଵ
× 100% (3-5) 
where 𝐴(𝑡) is the amount of peptide released at time t, 𝐴ଵ is the amount of peptide released on day 
1, 𝐴௅ is the amount of peptide loaded in the microspheres. 
 Statistical Analysis  
All data were expressed as mean ± SEM (n=3 or specifically indicated). Statistical analyses 
were carried out using GraphPad Prism 8.0.2 software. An ANOVA test was performed to 
determine the significance. The level of significance was established at the 95% confidence 
interval (α = 0.05). 
 Results 
 Effect of manufacturing parameters on EE of leuprolide 
In most of the formulations, the encapsulation efficiency of leuprolide was above 50% 
(Figure 3-10). The loading determined by one time extraction (Figure 3-1A) was slightly lower 
than the results determined by AAA (Figure 3-1B) due to the decreased recovery caused by 
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peptide-polymer interaction [118,129]. The effect of manufacturing parameters on the EE of 
leuprolide included: the substitution of ring-opening polymerized PLGA (Mw 15140, 75/25, 
acid-capped) in place of polycondensation PLGA (Mw 13887, 75/25, acid-capped) slightly 
increased the EE of leuprolide; when the gelatin was replaced by low bloom number gelatin, the 
EE was decreased while the substitution of similar bloom number gelatin did not significantly 
change the EE. To achieve a higher EE of leuprolide, higher polymer concentration, higher 1st 
homogenization speed, shorter homogenization time, lower 2nd water phase volume and higher 
stirring rate were preferred.  
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Figure 3-1. Loading of leuprolide determined by one-time extraction (A) and AAA methods (B). All values present as mean  
SEM (n=3). The dash lines indicate the desired loading of 10% w/w ± 5% or 10% specification. 
 
 Effect of manufacturing parameters on EE of gelatin  
During development of composition equivalent formulations, the EE of gelatin (101 ± 
1%) in the formulations loaded with gelatins with relative high bloom numbers (225 or 300) 
were observed to be much higher than the EE of LUP. The majority of formulations had 
desirable loading of 1.73% w/w gelatin (Figure 3-2), as in the LD. When the gelatin was 
replaced with Sigma 75, the EE was decreased. 
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Figure 3-2. Loading of gelatin. All values present as mean  SEM (n=3). The dash lines indicate the desired loading of 10% w/w 
± 5% specification. 
 
 Effect of manufacturing parameters on product attributes 
3.4.3.1 Morphology 
SEM micrographs indicated the LD microspheres (Figure 3-3A) were fine and small 
particles with smooth surface. The formulation made under the standard condition (Figure 3-3B) 
exhibited higher surface porosity compared to the LD. The figures of sectioned microspheres 
showed that the LD have small pores distributed homogeneously inside of the microspheres 
(Figure 3-3C). The standard condition microspheres had a denser polymer core under the porous 
surface (Figure 3-3D).  
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Figure 3-3. The SEM micrographs of (A) LD microspheres, (B) standard condition microspheres, (C) sectioned LD 
microspheres, and (D) sectioned standard condition microspheres. 
3.4.3.2 Particle size distribution 
The particle size distribution of LD was narrow with a volume median diameter (D (0.5)) 
(13.5  0.29 m) (mean  SEM, n=3) and the standard condition formulation showed a left 
skewed particle size distribution with a D (0.5) at 36.38  1.95 m (Figure 3-4A). The effect of 
manufacturing parameters on the particle size included (Figure 3-4B): replacement of polymer 
with Resomer polymer increased the particle size; using gelatin with low bloom number 
decreased the size; when the polymer concentration, primary water phase volume, 1st 
C D 
A B 
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homogenization speed and 2nd water phase volume were decreased, the particle size was 
decreased; and increasing 2nd homogenization time significantly decreased the particle size.   
 
Poly
mer 
prod
ucts
Gela
tin p
rodu
cts
Poly
mer
 con
cent
ratio
n
1s
t wate
r pha
se v
olum
e
1s
t hom
ogen
izati
on s
peed
1s
t hom
ogen
izatio
n tim
e
2n
d hom
ogen
izatio
n tim
e
2n
d wate
r pha
se v
olum
e
Stirr
ing r
ate
0
10
20
30
40
50
D
 (0
.5
) (
m
)
Level 1
Level 2 (Standard condition)
Level 3
LD
B
 
Figure 3-4. (A) Particle size distribution of LD and standard condition formulation and (B)Median diameters (D 0.5) of the 
formulations. The columns indicate mean  SEM (n=3). 
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3.4.3.3 Glass transition temperature (Tg)  
Figure 3-5 displays Tg for raw polymer, LD and formulations. The Tg of the raw Wako 
polymer was observed to be 39.6 0.3 °C and 49.5  0.1 °C for the standard condition 
formulation (w/ mannitol) (Figure 3-5A&B), consistent with the well-known PLGA-leuprolide 
interaction upon microspheres form [1]. The Tg of LD microspheres (w/ mannitol) (49.4  
0.2 °C) and standard condition formulation (w/ mannitol) were not significantly different 
(p>0.05). The standard condition formulation (w/o mannitol) exhibited a Tg of 49.4  0.2 °C, 
indicating the presence of mannitol in the formulations did not significantly affect the Tg 
(p>0.05) (Figure 3-5B). In addition, the measured Tg values for all other formulations prepared 
with the Wako polymer were very close to that of commercial product and standard condition 
formulation (Figure 3-5C). The Tg of raw Resomer polymer was measured as 46.2 0.1 °C, and 
the microspheres prepared by this polymer had a Tg of 51.5 °C. In the formulations 
prepared by Wako polymer, the loading of peptide varied in a relatively narrow range and 
showed no significant difference from the LD. The Tg of Resomer polymer was 6.6 °C higher 
than that of Wako but the increased Tg in microspheres relative to raw polymer was only ~5°C. 
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Figure 3-5. Glass transition temperatures (Tg) of (A) raw polymers, (B) LD, standard condition formulation w/ or w/o mannitol 
and Resomer microspheres, and (C) all other formulations. Data represent mean ± SEM (n=3).   
3.4.3.4 Residual moisture, solvent and porosity 
The water content of the LD was determined by Karl Fischer titration to be 0.14  
%. The prepared formulations showed higher residual water content and the majority of them 
showed the values around 1-2% (Figure 3-6). The highest residual moisture was observed in the 
formulation prepared with low 1st water phase volume and shortest 2nd homogenization time. The 
residual content of DCM in LD was lower than 1 ppm. The prepared formulations showed 
residual DCM in the range of 0.02-0.2% (Figure 3-7). The porosity of the LD was 7.5% (n=2) 
while the porosity of the standard condition formulation was observed to be 47% (n=2). The 
other prepared formulations also showed higher level of porosity compared to LD and no 
significant difference was observed in the group of formulations prepared with different 2nd 
homogenization time (Figure 3-8).  
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Figure 3-6. Residual moisture of formulations. Data represent mean ± SEM (n=3). The dash line indicates the value for LD. * p 
≤ 0.05.   
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Figure 3-7. Residual DCM of formulations. Data represent mean ± SEM (n=3). * p ≤ 0.05. 
 
Figure 3-8. Porosity of formulations in raw material and 2nd homogenization time groups. Data represent mean ± range (n=2). 
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 Release kinetics  
The cumulative release of LD in PBST lasted for 7 weeks with a 22.8  0.4% initial burst 
on day one followed by a zero-order release after day three. The release of peptide from prepared 
formulations showed similar release pattern (Figure 3-9). In each parameter group, when the 
formulation had a higher EE, it usually followed with higher initial burst. The loading and 
release of leuprolide in each formulation was normalized to the values of the standard condition 
formulation and the comparison is shown in Figure 3-10. When the formulation was prepared 
with the Resomer polymer, it showed a higher EE and higher initial burst but the release slowed 
down after 7 days and exhibited slower release compared to the standard condition formulation 
(0.93 %/day for Resomer formulation vs 1.12 %/day for standard condition formulation; 
1.05 %/day for LD based on least squared slope for 7-63 days). The release mechanisms of 
standard condition formulation, Resomer formulation and LD appeared to be the same (Figure 
3-11) and likely to be governed by a combination of factors (desorption and mass loss) [119]. In 
each case, the kinetics of peptide release was faster than mass loss. Slightly slower mass loss rate 
from Resomer formulation was consistent with its slower peptide release.  
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Figure 3-9. Release kinetics of formulations in different variable groups. Data represent mean ± SEM (n=3). The values in the 
parenthesis are the loading of peptide in each formulation.   
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Figure 3-10. Relationships between normalized initial burst and loading. Data represent mean ± SEM (n=3).   
 
 
Figure 3-11. Kinetics of release after initial burst plotted against mass loss kinetics. Data represent mean ± SEM (n=3). 
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Based on the ionic interaction between basic residual of amino acids in the leuprolide and 
carboxylic group in the polymer chains, Okada et al [83] proposed the drug core structure in the 
microspheres loaded with leuprolide where polymer chain served as a hydrophobic diffusion 
barrier. We observed ~ 60% EE of the leuprolide and ~100% EE of the gelatin (Figure 3-1 and 
Figure 3-2). The loss of peptide mainly occurred during the 2nd homogenization step and the loss 
content increased as homogenization intensity increased (Figure S 3-1). In our study, small 
microspheres were preferably prepared. Thus, a balanced protocol was established to produce 
microspheres with desired EE, particle size and release kinetics due to the efficiency of the 
homogenizer and small sample size. Both leuprolide and gelatin are considered water soluble, 
but gelatin is only readily dissolved at relatively high temperature [117]. Though leuprolide and 
gelatin were fully dissolved in the primary water phase at 60 °C, the temperature of the primary 
emulsion formed after homogenization was close to room temperature (see in Chapter 4, Table 
4-1). It is assumed that the gelatin in the disperse phase became a rigid gel-like structure and 
cannot easily migrate into the outer water phase during the second homogenization.  
The effect of raw materials/manufacturing variables on EE of leuprolide and D (0.5) were 
shown in (Figure 3-1 and Figure 3-4B) and also summarized in Table S 3-1. When the Wako 
PLGA was replaced with the Resomer polymer, increased EE and slightly larger particle size 
were obtained in the formulation. The Resomer 752H has similar average molecular weight to 
Wako polymer but the polymer solution of the formulation showed higher viscosity, which also 
raised the viscosity of the primary emulsion (data not shown) and finally decreased the drug loss 
during manufacturing. Gelatin products with bloom numbers 75, 225 and 250 were used to 
prepare three different microspheres. The EE of leuprolide and gelatin in microspheres loaded 
with gelatins with relatively high bloom numbers were comparable while the EE for both 
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ingredients was lower in the formulation with low bloom number gelatin (Figure 3-1 and Figure 
3-2). The bloom number typically affects the gelatin molecular weight [117] and solution 
viscosity [132]. The low viscosity of the gelatin 75 solution might be the reason for decreased 
EE as the primary emulsion size would be expected to be smaller, increasing the mobility and 
escape of the disperse phase droplets.  
When the polymer concentration was decreased from 500 and 600 mg/mL to 400 mg/mL, 
a drop in the EE of peptide and median diameter of microspheres were observed (Figure 3-1 and 
Figure 3-4B). The concentrated polymer solution is expected to shorten the evaporation time of 
DCM [57], and thus more strongly inhibit drug leakage from the polymer matrix to the outer 
water phase [53,55]. The effect of W1/O ratio on the EE of drug could be complex. Lower W1/O 
ratio (i.e., lower primary water phase) usually results in an efficient emulsification to form the 
primary emulsion with good quality and minimize the drug loss during the secondary 
emulsification [55–57]. But lower primary water phase may also produce smaller microspheres 
[37,60] with relatively low EE of peptide. Ogawa et al [118] observed increased EE of peptide as 
the particle size of microspheres increased. The water phase volume range (100, 120 and 150 
µL) selected in this study did not significantly affect the EE of peptide (Figure 3-1) while 
slightly decrease the particle size when the smaller primary aqueous phase volume was used. The 
1st homogenization speed range (8000, 10000 and 12000 rpm) selected in this study did not 
significantly affect the EE of peptide but low homogenization speed slightly decreased the EE, 
which was probably due to the larger emulsion droplets size that increased the chances of drug 
leakage. However, a significant reduction in the EE of peptide was obtained when the 1st 
homogenization time increased. Another dramatic decrease of peptide EE occurred when the 2nd 
homogenization time or secondary water phase volume was increased. The intensity of 2nd 
85 
 
homogenization seems to be the critical factor that affects both EE of peptide and particle size. 
Particularly, when larger water phase was mixed with the primary emulsion, the emulsification 
efficiency was reduced and led to increased particle size [55,60]. Stirring rate is expected to 
affect the particle size by controlling break-up of emulsion into small droplets [54,61,63]. In our 
study, the dispersion of the oil phase into the water phase and separation of nascent emulsion 
droplets occurred during the 2nd emulsification by the high shear force provided by the 
homogenizer. Since the soft microspheres droplets already formed before the in-liquid drying 
step, the stirring rate mainly affected the solvent removal rate. Higher stirring rate will lead to 
faster evaporation of DCM [93] and solidification of microspheres, and slightly increased EE of 
peptide was observed in this case.  
The Tg of microspheres is mainly affected by the Tg of raw polymer and the interaction 
between leuprolide and polymer chains. When leuprolide acetate was loaded into microspheres, 
the basic amino acid residuals in peptide interacted with the carboxylic group in the polymer 
chains [83] and formed salts throughout the polymer matrix, increasing the Tg. Okada et al found 
the Tg of the leuprolide loaded microspheres increased gradually from 42 to 47 °C as the loading 
increased in the range of 0-8 % [1,84]. However, in our study, for all microspheres prepared with 
Wako polymer displayed same ΔTg (~10 °C) independent of the peptide loading. As the loading 
of peptide was always ~10%, it is possible that the reported effect has a plateau at high peptide 
loading (> 8%). Though the Resomer polymer showed a higher Tg than the Wako polymer, the 
ΔTg during the encapsulation of peptide was only ~ 5 °C.  
The residual moisture and residual DCM level for LD was lower than the formulations 
prepared. Particularly, the residual DCM in LD was lower than the lowest detection limitation 1 
ppm. These results indicated the in-water drying protocol on a large scale is capable of achieving 
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low levels of organic solvent in the manufactured microspheres. DCM is classified as solvent to 
be limited in USP General Chapter <467> with the permitted daily exposure (PDE) at 6 mg/day 
[133]. The concentration limit could be calculated by [133]:  
Concentration (ppm) = (1000 µg/mg × PDE (mg/day))/ Dose (g) (3-6) 
The total amount of 1-Month LD product in a single administration is 88.2 mg. Since most of the 
formulations in this study were considered as composition-equivalent and similar dose was 
proposed to calculate the concentration of DCM exposure. The maximum concentration of DCM 
in the formulations was 0.19% and the corresponding amount of DCM in the formulation dosed 
was 0.17 mg, which was lower than the PDE. When the microspheres were prepared with 
shortest 2nd homogenization time, they displayed the high residual levels of both water and 
DCM. This is probably due to the relatively large particle size that increased the distance for the 
solvent to be transported through the polymer matrix and evaporate. When the 2nd water phase 
volume was increased, the residual DCM was also increased. The DCM close to the surface of 
the nascent microspheres was removed quickly, which facilitated the formation of a thick skin 
layer impeding further removal of solvent [58]. Since solvents, like water and DCM, affect the 
polymer relaxation and work as plasticizer on PLGA [134], the Tg of formed microspheres might 
be regulated by residual solvent content. However, in this study, we did not see significant 
difference of Tg in the formulations with different levels of residual solvents. This may indicate 
that the current difference of residual solvent is not large enough to induce significant changes 
on the microsphere Tg. 
The release kinetics for all formulations were highly similar to LD. The biggest 
difference in the release curves was caused by the initial burst. The theoretical loading of 
leuprolide was kept constant in the formulation, but the actual loading varied based on the 
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different input variables. The increased loading of water-soluble drug caused a slightly higher 
concentration gradient that induced more drug diffusion to release medium. The microspheres 
prepared with Resomer polymer had a slightly larger particle size, higher loading of peptide and 
higher initial burst. Meanwhile, studies have shown that increased Tg might decrease the long-
term release rate [51,135]. The Tg of both the raw Resomer polymer or the final microspheres 
were higher than those based on the Wako polymer. After the initial burst, Resomer 
microspheres showed slightly slower release rate compared the Wako microspheres consistent 
with the slightly slower polymer erosion. The composition-equivalent microspheres showed 
much higher porosity than the LD and they were expected to release the peptide more quickly. 
However, the release of peptide is very insensitive to the length-scale of the PLGA matrix at 
least when above a certain matrix size [136]. Moreover, the peptide is expected to be released by 
diffusion mechanisms after the initial burst [119]. 
 Conclusions 
The composition, Tg, and in vitro release kinetics of PLGA microspheres loaded with 
leuprolide can be largely replicated on the bench scale relative to the LD. The encapsulation 
efficiency of leuprolide was lowered than that of gelatin. The substitution of ring-opening 
polymerized PLGA in place of polycondensation PLGA increased Tg, EE and initial burst, and 
slightly reduced long-term release rate. Changing manufacturing variables centered at a standard 
formulation did not strongly affect release behavior. Changes in initial burst release mirrored 
changes in drug loading/encapsulation efficiency. 
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 Supplementary material
Table S 3-1. Effect of increased variables on the EE of leuprolide and D (0.5) in formulations.  
Parameters ↑ Change of EE Change of D (0.5) 
Polymer supplier/  Resomer ↑ Resomer ↑  
Gelatin bloom number ↑ ↑ 
Polymer concentration ↑ ↑ 
1st water phase volume Not significant ↑ 
1st homogenization speed (slightly) ↑ ↑ 
1st homogenization time ↓ Standard is the smallest 
2nd   homogenization time  ↓ ↓ 
2nd water phase volume ↓ ↑ 
Stir rate (rpm) ↑ Not significant 
Note: ↑ and ↓ indicates upregulation and downregulation. 
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Figure S 3-1. Kinetics of leuprolide loss during secondary homogenization process and in-liquid drying process. 
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Chapter 4 Mechanistic understanding of microsphere formation 
 
 Abstract 
The emulsion-based microencapsulation method for producing PLGA microspheres 
suffers from batch-to-batch variation and scale-up difficulties. This study aimed to develop a 
detailed understanding of the effects of process variables on the complex emulsification 
processes during encapsulation of leuprolide in PLGA microspheres using a high-shear rotor-
stator mixer. Multiple variables during the formation of primary and secondary emulsion were 
investigated, including: rotor speed (ω) and time (t), dispersed phase fraction (Φ) and continuous 
phase viscosity (µc). The dimensionless Sauter mean diameter of primary emulsion droplet was 
observed to be proportional to the product of several key dimensionless groups 
(𝛷ଵ, 𝑊𝑒, 𝑅𝑒, 𝜔ଵ𝑡ଵ) raised to the appropriate power indices. A new dimensionless group (total 
surface energy/total energy input to fluid) was used to rationalize insertion of a proportionate 
time dependence in the scaling of the Sauter mean diameter. The increased viscosity of primary 
emulsion inhibited drug loss during microencapsulation consistent with literature reports while 
increased droplet size enhanced drug leakage to the outer water phase. The dimensionless Sauter 
mean diameter of secondary emulsion was found proportional to the product of three 
dimensionless groups (Φଶ,
ఓభᇲ
ఓ೎మ
, 𝜔ଶ𝑡ଶ) raised to the appropriate power indices. The results will be 
useful for dimensional analysis and improving formulation and manufacturing of PLGA 
microspheres by the solvent evaporation method. 
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 Introduction 
Microspheres loaded with water-soluble peptide prepared by double emulsion-solvent 
evaporation method involves two emulsification steps: 1) emulsification of aqueous peptide 
phase into organic polymer phase (W1/O) and 2) further emulsification of liquid emulsion 
(W1/O) in aqueous phase (W2) to form a complex emulsion for microsphere formation. Both 
steps include key parameters that may affect the attributes of final microspheres, e.g., 
encapsulation efficiency (EE) of peptide, particle size, and polymer microstructure. The current 
emulsion-based microencapsulation process is based on trial and error and has batch-to-batch 
variation and scale-up difficulties [92,93]. Experimental approaches and quantitative correlations 
have been developed to improve the understanding of how microencapsulation process influence 
the final product attributes. 
Multiple reports [1,137,138] have indicated that the emulsion viscosity, droplet size and 
stability could affect the drug loading and particle size of the microspheres. The loss of drug 
during the microencapsulation process has been described by different mechanisms. Alex and 
Bodmeier [138] indicated the drug was lost from inner water phase to the outer water phase by 
diffusion through polymer phase or internal water channels. They found decreasing polymer 
concentration or increasing inner water phase volume could decrease EE of the drug [138]. The 
inventors of Lupron Depot® found that decreasing the temperature of the primary emulsion 
dramatically increased the viscosity of the emulsion, and high EE of peptide was obtained 
[54,86]. Maa and Hsu [137] explained the drug loss by using hydrodynamic model [139]. The 
microspheres were formed by liquid drop fragmentation mechanism [137]. Turbulent flow 
generates eddies with different interfacial velocities on the liquid droplets which causes dynamic 
pressure difference across the droplet [137]. The fragmentation of drops happens when the 
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pressure difference is higher than the interfacial tension and other cohesive forces [137]. Low 
viscosity of inner water phase or large droplet size readily induce such fragmentation and the 
internal aqueous droplets are exposed to outer water phase during secondary emulsion and 
causes drug leakage [137]. 
Viscosity (𝜇) and droplet size (𝑑) of the emulsion have been reported to be correlated to 
[96,97,104–106]: continuous phase viscosity (𝜇௖) and density (𝜌௖), dispersed phase viscosity 
(𝜇ௗ) and density (𝜌ௗ), dispersed phase volume fraction (Φ), interfacial tension (σ), rotor speed 
(𝜔), and mixing time/pass times (𝑡). Krieger and Dougherty [114] proposed an empirical model 
for relative viscosity when the Φ is low based on Einstein equation [111,112] and Taylor [113] 
equations: 
𝜇
𝜇௖
= 1 + (
𝜇ௗ
𝜇௖
− 1)Φ (4-1) 
The relationships between the geometry, rotor speed, and the energy dissipation of the 
homogenizer have been studied [94,97–100]. The first step is to link the energy dissipation rate 
to geometry and rotor speed [94]. Atiemo-Obeng [101] indicated that the definition of power 
number (𝑃ை) and Reynolds number (𝑅𝑒) for rotor-stator mixer could be the same as those for 
conventional stirred tanks. When impeller type and thickness, and turbulent flow conditions are 
assumed to be constant, 𝑃ை becomes nearly constant [102]. The Reynolds number is 
𝑅𝑒 =
𝜌𝜔𝐷ଶ
𝜇
=
𝜔𝐷ଶ
𝑣
 (4-2) 
where 𝜇 is the fluid dynamic viscosity, 𝜌 is the liquid density, 𝜔 is impeller speed and 𝐷 is rotor 
diameter. In the full turbulent regime (𝑅𝑒 is above ~104), the 𝑃ை is constant of Reynolds number 
[94] but dependent on the geometry of rotor-stator. The concept developed by Kolmogorov has 
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been widely used to describe the turbulent eddies [95,103]. The Kolmogorov length scale (𝛿௄) is 
expressed as:  
𝛿௄ = (
𝑣ଷ
ε
)ଵ/ସ (4-3) 
where ε is the local energy dissipation rate per unit mass of fluid. For isotropic turbulence, ε can 
be expressed as the energy loss rate from mixer to the fluid divided by the mass of fluid (𝜌𝑉) 
[52,93]: 
ε =
𝜔ଷ𝐷ହ𝑃ை
𝑉
 (4-4) 
Then the 𝛿௄ is 
𝛿௄ = ቈ
𝑉𝑣௖ଷ
𝜔ଷ𝐷ହ𝑃ை
቉
ଵ/ସ
= ቎
𝑉(𝜇௖𝜌௖
)ଷ
𝜔ଷ𝐷ହ𝑃ை
቏
ଵ/ସ
 
(4-5) 
The Sauter mean diameter (𝑑ଷ,ଶ), which is defined as the ratio of third and second 
moments of a particle size distribution, has been used to study the effect of processing variables 
on the physical properties of emulsion [95]. Based on the values of 𝛿௄ and droplet size, and the 
viscosity of the solution, different correlations to predict particle size from dimensionless groups 
have been studied and summarized by Calabrese [92], Leng [107] and Hall et al [95,96]. Rotor 
stator mixers usually produce droplets with the diameter (𝑑) on the order of 𝛿௄ and smaller (𝛿௄ > 
𝑑), and if the stress on drop is inertial, the following correlation exists [92]: 
𝑑ଷ,ଶ
𝐷
∝ (𝑊𝑒𝑅𝑒)ି 
ଵ
ଷ (4-6) 
where 𝑊𝑒 is the Weber number and defined as  
𝑊𝑒 = 𝜌𝜔ଶ𝐷ଷ/σ (4-7) 
When  𝛿௄ >> 𝑑, the correlations is [92]: 
94 
 
𝑑ଷ,ଶ
𝐷
∝ (𝑊𝑒𝑅𝑒ସ)ି 
ଵ
଻ (4-8) 
If the droplets are broken by turbulent viscous stress, the relationship becomes [92]: 
𝑑ଷ,ଶ
𝐷
∝ (𝑊𝑒ିଵ𝑅𝑒ଵ/ଶ) (4-9) 
Leng and Calabrese [107] established a correlation between dispersed phase volume and 
droplet size in the stirred vessel system: 
𝑑ଷ,ଶ
𝐷
= 𝐶ଵ(1 + 𝐶ଶΦ)𝑊𝑒ି଴.଺ (4-10) 
where 𝐶ଵ and 𝐶ଶ are constants related to geometry of device and coalesce characteristics of 
system. A generalized form of the models has been reported as [140]: 
𝑑ଷ,ଶ
𝐷
= 𝐶ଷ𝑊𝑒௔𝑅𝑒௕(
𝜇ௗ
𝜇௖
)௖ (4-11) 
where 𝑎 was found to be -0.6 in many studies [141]. 
This study aims to provide more understanding of effect of manufacturing variables on 
the emulsification process using a high-shear rotor-stator mixer by testing the existing 
correlations in the literature or identifying appropriate relationships that could be applied to a 
definitive dimensional analysis in the future.  
 Materials and Methods 
 Chemicals and Reagents 
Leuprolide acetate with purity more than 99% by high-performance liquid 
chromatography (HPLC) analysis was purchased from Bachem Americas Inc. (Torrance, CA, 
USA). Type B gelatin derived from porcine skin with bloom number 300 (beMatrixTM Low 
Endotoxin Gelatin LS-W) was purchased from Nitta Gelatin Inc. (Osaka, Japan). Wako 7515 
PLGA polymer was purchased from Wako Pure Chemical Industries, Ltd. (Tokyo, Japan). 
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Polyvinyl alcohol (PVA) (GOHSENOLTM EG-40P) was purchased from Soarus L.L.C. 
(Arlington Heights, IL, USA). All solvents used were HPLC grade and were purchased from 
Fisher Scientific.  
 Preparation of double emulsions 
Double emulsions were prepared according to the solvent evaporation protocol described 
in Chapter 3 as a function of manufacturing variables listed in the formulation table (Table 3-1). 
Briefly, the standard condition is shown below and from which emulsions were prepared by 
changing one variable at a time. Wako PLGA (500 mg) was dissolved in 1 mL methylene 
chloride (DCM). Gelatin (bloom number 300) (10.6 mg) and leuprolide acetate (100 mg) were 
dissolved in 120 L ddH2O at 60 °C. The oil phased was transferred to the water phase and 
immediately vortexed for 20 s followed by emulsification using a VirTis Tempest IQ2 
homogenizer (SP Scientific Inc., Warminster, PA, USA) at speed 10000 rpm for 2 min to form a 
W1/O emulsion. The obtained W1/O emulsion was cooled in ice bath for 2 min to increase the 
viscosity of the primary emulsion. Then 2 mL aqueous 0.25% PVA solution was mixed with the 
cooled primary emulsion by vortex for 20 s and homogenization at 15000 rpm for 30 s to form 
the secondary emulsion, i.e. a W1/O/W2 emulsion.  
 Determination of viscosity 
The viscosity of primary and secondary emulsion, and other samples at room temperature 
were determined by microVISC™ viscometer (Rheosense, Inc., San Ramon, CA, USA). The 
room temperature in the lab was ~23.5 °C. The sample was injected into the measuring cell that 
contains a rectangular slit flow channel at a constant flow rate where multiple pressure sensors 
monitored the pressure drop from the inlet to the outlet [142]. The pressure drop was correlated 
with the shear-stress and the shear rate and shear stress were related to the geometry of the 
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rectangular slit and the flow rate [142]. The viscosity of the primary emulsion after cooling 
process was determined by m-VROC viscometer (Rheosense, Inc., San Ramon, CA, USA) with 
temperature precisely controlled at 4 ± 0.15 °C.  
 Determination of emulsion size 
The size of primary emulsion droplets was determined by a Zeiss Axio Lab light 
microscopy (Carl Zeiss AG, Oberkochen, Germany) equipped with 40X objectives. Briefly, the 
emulsion was added to the glass microscope slide and glass cover was placed over the sample. 
The pictures of emulsions were taken by a Cannon camera. MATLAB was used to identify the 
boundary of each droplet and the particle size distribution. The Sauter mean diameter was 
calculated by: 
𝑑ଷ,ଶ =
∑ 𝑑௜ଷ௡௜ୀଵ
∑ 𝑑௜ଶ௡௜ୀଵ
 (4-12) 
where 𝑑௜ is the diameter of the ith droplet. 
The size of secondary emulsion droplets was determined using a Malvern Mastersizer 
2000 (Malvern Instruments Ltd., Worcestershire, UK). A certain volume of the emulsion 
solution was added in the instrument sample dispersion unit to enable the obscuration of the 
sample around ~10%. Three measurements were performed per sample at a stirring speed of 
2500 rpm and sampling time of 15 s. To achieve repeatable results, all samples were measured 
within 10-15 min after the secondary emulsions were formed.   
 Dimensional analysis 
The number of particles (𝑁௣) could be calculated by the total mass and mass of particles: 
𝑁௣ =
ρௗVௗ
ρௗ
4
3 𝜋𝑟ଷ,ଶ
ଷ
=
6Vௗ
𝜋𝑑ଷ,ଶଷ
 (4-13) 
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where ρௗ is the density of the dispersed phase and 𝑟ଷ,ଶ is the radius of the particles. Then the 
total surface energy of particles is: 
𝛾 = 𝑁௣ ∙ 4𝜋𝑟ଷ,ଶଶ ∙ 𝜎 = 6𝑑ଷ,ଶିଵVௗ𝜎 (4-14) 
Based on equation (4-4), the input energy on fluid could be calculated by: 
ε ∙ ρ௖V ∙ t = ρ௖𝜔ଷ𝐷ହ𝑃ை𝑡 (4-15) 
Thus, the ratio of input energy and surface energy (Χ) is: 
Χ =
𝜌௖𝜔ଷ𝐷ହ𝑃ை𝑑ଷ,ଶ𝑡
6𝑉ௗ𝜎
∝
𝜌௖𝜔ଷ𝐷ହ𝑃ை𝑑ଷ,ଶ𝑡
𝑉ௗ𝜎
 (4-16) 
The ratio of 𝛿௄ and 𝑑ଷ,ଶ is: 
Y =
𝛿௄
𝑑ଷ,ଶ
= ቎
𝑉(𝜇௖𝜌௖
)ଷ
𝜔ଷ𝐷ହ𝑃ை
቏
ଵ/ସ
1
𝑑ଷ,ଶ
 
(4-17) 
The dimensionless groups Χ and Y were used to develop non-dimensional correlations between 
emulsion size and process variables. 
 Results and discussion 
 Effect of manufacturing variables on primary emulsion viscosity and droplet size 
The experimental conditions and parameters of primary emulsion are summarized in 
Table 4-1. When the concentration of polymer was increased, the viscosity of continuous phase 
(µ௖భ) and µଵ both significantly increased (Figure 4-1A). When the 1
st homogenization time (𝑡ଵ) 
increased from 60 s to 180 s, the viscosity of primary emulsion (µଵ) slightly decreased, and the 
correlation could be described by a linear regression (Figure 4-1B). In the series of composition-
equivalent formulations used to define the emulsification conditions studied here, the theoretical 
loading of peptide and gelatin were controlled at constant values. When the polymer 
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concentration was increased, the amount of drug was also increased while the volume of water 
phase was not changed. Then the concentration of drug as well as the viscosity (µௗ) of the 
dispersed phase was increased. The primary water phase is a highly concentrated solution of 
leuprolide and gelatin, and µௗ >> µ௖భ. Based on equation (4-1), it is expected the viscosity of 
primary emulsion #1-3 is dramatically increased. The results (Table 4-1) also indicated 
increasing 1st homogenization speed (𝜔ଵ) or increasing water phase volume within relatively 
narrow ranges (8000 - 12000 rpm for 𝜔ଵ, and 0.10 - 0.15 for Φଵ) did not significantly affect the 
emulsion viscosity.  
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Table 4-1. Summary of characteristics of primary emulsions formed. 
Emulsion # 𝐶௣ 
(mg/mL) 
µ௖భ
*  
(mPa·s) 
𝛷ଵ 
 
𝜔ଵ 
(rpm) 
𝑡ଵ 
(s) 
𝑇ଵ 
(°C) 
𝑑ଵ* 
(µm) 
𝑑ଷ,ଶ  
(µm) 
µଵ* 
(mPa·s) 
µଵᇱ * 
(mPa·s) 
1-1 500 23.64 ± 0.03 0.12 10000 120 29.0 1.74 ± 0.01 2.62 122.2 ± 0.6 1281 ± 35 
1-2 400 17.87 ± 0.01  0.12 10000 120 24.7 0.63 ± 0.01 2.23 62.1 ± 0.3 550 ± 6 
1-3 600 48.62 ± 0.08 0.12 10000 120 30.3 5.31 ± 0.02 5.50 239.7 ± 6.1 3131 ± 17 
1-4 500 23.64 ± 0.03 0.1 10000 120 28.7 1.45 ± 0.02 2.88 111.1 ± 1.1 787 ± 88 
1-5 500 23.64 ± 0.03 0.15 10000 120 28.7 1.83 ± 0.02 2.33 116.5 ± 1.2 1768 ± 20 
1-6 500 23.64 ± 0.03 0.12 8000 120 26.9 2.11 ± 0.02 4.77 107.2 ± 2.2 1032 ± 56  
1-7 500 23.64 ± 0.03 0.12 12000 120 28.3 0.74 ± 0.01 1.43 115.3 ± 2.4 1098 ± 52  
1-8 500 23.64 ± 0.03 0.12 10000 60 27.9 2.87 ± 0.07 4.28 131.4 ± 2.7 1444± 30 
1-9 500 23.64 ± 0.03 0.12 10000 180 28.4 0.95 ± 0.01 2.11 99.1 ± 2.0 1199± 42 
Note: Cp: polymer concentration; µc1: viscosity of primary continuous phase; Φ1: dispersed phase fraction in primary emulsion; ω1: 1s homogenization speed; t1: 1st 
homogenization time; T1: temperature after 1st homogenization; d1: mean droplet size of primary emulsion; d3,2:Sauter mean diameter of primary emulsion; µ1: viscosity of 
primary emulsion at room temperature; µ1’: viscosity of primary emulsion at 4 °C. * values indicate mean ± SEM.  
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Figure 4-1. Correlations between primary emulsion viscosity with (A) continuous phase concentration and (B) homogenization 
time. 
The correlations between primary emulsion droplet size (𝑑ଷ,ଶ) with (A) dispersed phase 
fraction, (B) 1st homogenization speed, (C) 1st homogenization time and (D) viscosity of 
continuous phase were fitted by power law with index -0.52, -2.96, -0.65 and 0.93, respectively 
(Figure 4-2). The indices allowed the establishment of a correlation between 𝑑ଷ,ଶ and 
independent variables: 
𝑑ଷ,ଶ = 𝑓(𝑉ௗ, 𝑉௖ , µ௖భ , 𝜌௖ , 𝜔ଵ, 𝑡ଵ, 𝜎, 𝐷) (4-18) 
where 𝑉ௗ and 𝑉௖ are the volume of the dispersed phase and continuous phase and Φଵ could be 
expressed by ௏೏
௏೎
. There are nine variables in equation (4-18), then 9-3 = 6 independent 
dimensionless groups are needed to describe dimensionless Sauter mean diameter:  
𝑑ଷ,ଶ
𝐷
= 𝑓(Φଵ, 𝑊𝑒, 𝑅𝑒, 𝜔ଵ𝑡ଵ,
𝐷ଷ
𝑉௖
) (4-19) 
where the 𝑅𝑒 and 𝑊𝑒 could be calculated by equations (4-2) and (4-7). The interfacial tension 
between DCM and water has been reported at 28.3 mN/m [143,144]. In this study, both 𝐷 and 𝑉௖ 
were constant and the equation (4-19) was reduced to: 
µ1 = 10-7 Cp3.3212
R² = 0.9968
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𝑑ଷ,ଶ
𝐷
∝ 𝑓(Φଵ, 𝑊𝑒, 𝑅𝑒, 𝜔ଵ𝑡ଵ) (4-20) 
Based on the generalized form in (4-11), the power assigned to the Weber number was -0.6. The 
appropriate index for the other dimensionless groups were determined by using the relationships 
in Figure 4-2. The dimensional correlation between 𝑑ଷ,ଶ and product of 
(𝑉ௗି଴.ହ𝑉௖଴.ହ𝜇௖ଵ.ଵଷ𝜌௖ିଵ.଻ଷ𝑡ଵି଴.଺଺଻𝜔ଵିଷ𝜎଴.଺𝐷ିଷ) is shown in Figure 4-3A and the correlation 
between ௗయ,మ
஽
 and product of dimensionless groups (i.e., Φଵି଴.ହ𝑊𝑒ି଴.଺ 𝑅𝑒ିଵ.ଵଷ(𝜔ଵ𝑡ଵ)ି଴.଺଺଻) is 
shown in the insert. Excellent linearity between the process variables and 𝑑ଷ,ଶ was found with 
R2=0.99.  
Another approach to develop the correlates included the dissipation of total input energy 
to the fluid and surface energy of the formed droplets. The dimensionless groups X and Y 
(equations (4-16) and (4-17)) were created to predict the size of the emulsion size. The product 
of Χି
మ
య and Y
ర
య is: 
Χି
ଶ
ଷY
ସ
ଷ ∝
Vௗ
ଶ
ଷV௖
ଵ
ଷ𝜎
ଶ
ଷ𝜇௖భ
ρ௖భ
ହ
ଷ𝜔ଵଷ𝐷ହ𝑃ை𝑡ଵ
ଶ
ଷ𝑑ଷ,ଶଶ
 
(4-21) 
To obtain the correct power index of variables, dimensionless groups ቀ௏೏
௏೎
ቁ
ି଻/଺
 and ஽
య
௏೎
 were also 
introduced, then:  
𝑑ଷ,ଶ
𝐷
∝ 𝑋
ଶ
ଷ𝑌ି
ସ
ଷ ൬
𝑉௖
𝐷ଷ
൰
ଵ
൬
𝑉ௗ
𝑉௖
൰
଻
଺
 
(4-22) 
𝑑ଷ,ଶ ∝ 𝑉ௗ
ିଵଶ𝑉௖
ଵ
ଶ𝜇௖భ
ଵ𝜌௖భ
ିହଷ𝑡ଵ
ିଶଷ𝜔ଵିଷ𝜎
ଶ
ଷ𝐷ିଷ (4-23) 
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This correlation was tested in Figure 4-3B and there is also a good linearity with R2=0.97. The 
dimensionless correlation above could also be expressed by using the same dimensionless groups 
as in the previous fitting (4-20): 
𝑑ଷ,ଶ
𝐷
∝ Φଵିଵ/ଶ𝑊𝑒ିଶ/ଷ 𝑅𝑒ିଵ(𝜔ଵ𝑡ଵ)ିଶ/ଷ (4-24) 
However, there is a deviation from linearity for the emulsions with large particle size. The 𝑑ଷ,ଶ 
of primary emulsion was significantly affected by the homogenization speed while the effect of 
homogenization time and dispersed phase fraction was weaker. 
      
      
Figure 4-2. Correlations between primary emulsion droplet size (d1) with (A) dispersed phase fraction and (B) homogenization 
speed, (C) homogenization time and (D) polymer concentration. 
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Figure 4-3. Generation of master curve for correlations between primary emulsion size and manufacturing variables. 
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 Effect of primary emulsion viscosity and droplet size on EE  
Primary emulsion viscosity before and after the cooling process, mean droplet size (𝑑ଵ) 
and the EE of peptide in the corresponding microspheres are shown in Figures 4-4 and 4-5. The 
viscosity of primary emulsion or primary water phase have been shown by Takeda [54] to be a 
critical step to achieve high EE of peptide. The cooling step significantly increased the viscosity 
of primary water phase (µଵᇱ ) for all emulsions (Figure 4-4). When the polymer concentration was 
increased from 400 mg/mL to 500 mg/mL, the viscosity of primary emulsion was increased 
(Figure 4-4A) and decreased the drug leakage from inner water phase to the outer water phase. 
When the Cp was further increased to 600 mg/mL, both the primary emulsion viscosity and the 
emulsion droplet size (Figure 4-5A) were increased. The later result might be an offset that 
prevents the EE elevation. A similar phenomenon was observed in the primary water phase 
volume group. The emulsion viscosity after cooling increased gradually as dispersed phase 
fraction was raised (Figure 4-4B) while the droplet size was also elevated (Figure 4-5B). Alex 
and Bodmeier [138] found that when the amount of water was increased, the thickness of 
polymer phase around the water phase decreased and more water droplets were connected with 
the continuous phase, leading to higher drug leakage. Therefore. the water phase volume range 
(100, 120 and 150 µL) selected in this study did not significantly affect the EE of peptide. By 
increasing the homogenization speed or increasing homogenization time, the droplet size was 
decreased (Figure 4-5 C&D). However, the viscosity of the emulsion appeared to be dominant 
factor that regulated the EE in these two groups (Figure 4-4 C&D). 
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Figure 4-4. Relationships between manufacturing variables, primary emulsion viscosity and EE of peptide. 
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Figure 4-5. Relationships between manufacturing variables, primary emulsion droplet size and EE of peptide 
 Effect of manufacturing variables on the secondary emulsion 
Secondary emulsions #2-1 - #2-9 (Table 4-2) were prepared from the primary emulsion 
listed in Table 4-1 with the same process variables during the 2nd homogenization step. 
Secondary emulsions #2-10 - #2-13 were prepared from primary emulsion #1-1 (standard 
condition) by changing 2nd homogenization time or 2nd water phase volume. When the secondary 
water phase volume was increased from 1 mL to 4 mL (𝛷ଶ decreased from 1 to 0.25), the 
viscosity of secondary emulsion decreased while the droplet size increased (Figure 4-6 A&C). In 
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the secondary emulsion, the dispersed phase was the cooled primary emulsion, which could also 
be considered as an oil phase with higher viscosity (µଵᇱ ), and the continuous phase was PVA 
solution with a much lower viscosity (µ௖మ) (Table 4-2). On the one hand, if the dispersed phase 
fraction 𝛷ଶ is high, an increase in the difficulty for the homogenizer to break up the droplet to 
small particle is expected [145]. On the other hand, when the ratio is controlled in an appropriate 
range, increased outer water phase volume is expected to reduce the emulsification efficiency 
and lead to increased particle size [55,60,146]. In this study, the high values of µଵᇱ  were caused 
by the low temperature after cooling the primary emulsion. After the secondary homogenization 
process performed at room temperature, the primary emulsion was dispersed into the water phase 
to form a less viscous emulsion (µ2) and the temperature (T2) was raised. In this case, 𝛷ଶ has a 
more significant effect on the droplet size (Sauter mean diameter) (𝑑′ଷ,ଶ) than on the viscosity. 
Based on the equation (4-10) developed by Leng and Calabrese [107], the data fit the correlation 
in equation (4-25) with a regression coefficient R2 =0.99: 
𝑑′ଷ,ଶ
𝐷
= 0.8(1 − 0.8Φଶ)𝑊𝑒ି଴.଺ 
(4-25) 
The correlation between homogenization time (t2) and viscosity was described by a 
power law with index of -1.15 (Figure 4-6B). The droplet size of secondary emulsion was 
correlated to homogenization time t2 by a power law fitting with index of -1.25 (Figure 4-6D). 
The dimensionless correlation between secondary emulsion size and process variables could be 
expressed by equation (4-26) with excellent R2 0.99 (Figure 4-7). 
𝑑′ଷ,ଶ
𝐷
∝ (1 − 0.8Φଶ)(𝜔ଶ𝑡ଶ)ିଵ.ଶହ (4-26) 
Secondary emulsions #2-1 - #2-9 were prepared using the primary emulsions generated in 
section 4.4.1 with constant 2nd emulsification process variables (i.e., 𝛷ଶ=0.5, 𝜔ଶ =15000 rpm 
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and 𝑡ଶ=30 s). Thus, the droplet size of these secondary emulsions is expected to be highly 
dependent on the dispersed phase viscosity, i.e., µଵᇱ . The dimensionless group, 
ఓᇱభ
ఓ೎మ
, was included 
to establish the correlation: 
𝑑′ଷ,ଶ
𝐷
∝ (1 − 0.8Φଶ) ቆ
𝜇′ଵ
𝜇௖మ
ቇ
଴.ହ
(𝜔ଶ𝑡ଶ)ିଵ.ଶହ 
(4-27) 
This correlate was tested in Figure 4-8 with a regression coefficient R2 = 0.98. The secondary 
emulsion size was significantly affected by homogenization time and secondary water phase 
volume while the viscosity of primary emulsion had a weaker effect.
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Table 4-2. Summary of characteristics of secondary emulsions formed. 
Emulsion # µଵ
ᇱ * 
(mPa·s) 
µ௖మ
* 
(mPa·s) 𝛷ଶ 𝜔ଶ (rpm) 𝑡ଶ (s) 𝑇ଶ (°C) 𝑑ଶ
* (µm) 𝑑′ଷ,ଶ* (µm) 
µଶ* 
(mPa·s) 
2-1 1281 ± 35 2.3 ± 0.1 0.50 15000 30.00 20.50 58.4 ± 0.4 20.9 ± 0.2 9.1 ± 0.6 
2-2 550 ± 6 2.3 ± 0.1 0.50 15000 30.00 18.60 28.6 ± 0.1 12.6 ± 0.1 7.1 ± 0.4 
2-3 3131 ± 17 2.3 ± 0.1 0.50 15000 30.00 18.60 83.7 ± 1.7 38.9 ± 0.8 18.5 ± 0.6 
2-4 787 ± 88 2.3 ± 0.1 0.50 15000 30.00 18.80 59.4 ± 1.0 20.8 ± 0.2 10.2 ± 0.4 
2-5 1768 ± 20 2.3 ± 0.1 0.50 15000 30.00 18.70 59.4 ± 0.6 23.9 ± 0.4 9.9 ± 0.5 
2-6 1032 ± 56 2.3 ± 0.1 0.50 15000 30.00 19.70 66.2 ± 0.3 27.8 ± 0.1 10.1 ± 0.8 
2-7 1098 ± 52 2.3 ± 0.1 0.50 15000 30.00 19.60 58.8 ± 0.9 19.4 ± 0.3 7.6 ± 0.5 
2-8 1444 ± 30 2.3 ± 0.1 0.50 15000 30.00 20.60 73.4 ± 1.6 26.6 ± 0.7 8.7 ± 0.1 
2-9 1199 ± 42 2.3 ± 0.1 0.50 15000 30.00 17.70 64.1 ± 1.4 18.6 ± 0.3 7.2 ± 0.4 
2-10 1281 ± 35 2.3 ± 0.1 0.50 15000 10.00 16.70 133.3 ± 4.1 87.4 ± 2.6 47.0 ± 2.1 
2-11 1281 ± 35 2.3 ± 0.1 0.50 15000 45.00 19.10 43.4 ± 3.2 13.7 ± 0.7 9.6 ± 0.5 
2-12 1281 ± 35 2.3 ± 0.1 1.00 15000 30.00 19.60 14.3± 0.3 7.2 ± 0.1 11.1 ± 0.4 
2-13 1281 ± 35 2.3 ± 0.1 0.25 15000 30.00 18.70 68.8 ± 0.5 28.7 ± 0.2 5.00 ± 0.8 
Note:µଵᇱ : viscosity of primary emulsion at 4 °C; µ௖ଶ: viscosity of secondary continuous phase; Φ2: dispersed phase fraction in secondary emulsion; ω2: 2nd homogenization speed; 
t2: 2nd homogenization time; T2: temperature after 2nd homogenization; d2: volume median droplet size of secondary emulsion; 𝑑′ଷ,ଶ: Sauter mean diameter of the secondary 
emulsion; µ2: viscosity of secondary emulsion at room temperature. * values indicate mean ± SEM. 
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Figure 4-6. Effect of dispersed phase fraction (Φ2) and homogenization time (t2) on secondary emulsion viscosity (µ2) (A&B), 
and Sauter mean diameter (d'3,2) (C&D). 
µ2 = 11.842Φ20.5811
R² = 0.9239
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
0.00 0.50 1.00 1.50
µ 2
(m
Pa
·s
)
Φ2
A µ2 = 607.85t2-1.148
R² = 0.9145
0.0
10.0
20.0
30.0
40.0
50.0
0.00 20.00 40.00 60.00
µ 2
(m
Pa
·s
)
t2 (s)
B
d'3,2 = 35.57(1-0.8Φ2)
R² = 0.9991
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
0.00 0.50 1.00 1.50
d'
3,
2
(µ
m
)
Φ2
C d'3,2 = 1519.4 t2-1.246
R² = 0.998
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
0.00 20.00 40.00 60.00
d'
3,
2
(µ
m
)
t2 (s)
D
d'3,2 = 0.473µ1'0.5421
R² = 0.7258
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
0.00 2000.00 4000.00
d'
3,
2
(µ
m
)
µ1' (mPa·s)
E
111 
 
0 1×10-5 2×10-5 3×10-5 4×10-5
0
2×10 -3
4×10 -3
6×10 -3
8×10 -3
1×10 -2
(1-0.8Φ2)×(ω2t2)-1.25
d'
3,
2
/D
R2=0.99
 
Figure 4-7. Effect of process variables during secondary emulsification step on the droplet size. 
 
Figure 4-8. Generation of master curve for correlations between secondary emulsion size and manufacturing variables. 
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 Relationships between manufacturing variables, secondary emulsion droplet size and EE 
of peptide are shown in Figure 4-9. The intensity of 2nd homogenization seems to be the critical 
factor that affects both EE of peptide and particle size. Another dramatic decrease of peptide EE 
happened when the 2nd homogenization time or secondary water phase volume increased. When 
the secondary water phase volume was increased from 1 mL to 4 mL (Φ2 decreased from 1 to 
0.25), there was a faster solvent removal rate due to the sink condition facilitating the DCM to 
dissolve in the outer aqueous phase [58]. In this case, solidification of periphery microspheres 
occurs quickly and a thick skin layer is formed [58] inducing the diffusion of peptide through the 
polymer phase to outer water phase [138]. It was previously shown in a pilot study that the drug 
loss increased as a function of homogenization time (Figure S 3-1). This result could be 
explained by the assumption that drug diffuses through the polymer matrix gradually as time is 
extended as well as the drop fragmentation theory [137] suggesting more drug leakage in the 
small droplets after exposure to the outer water phase. 
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Figure 4-9. Relationships between manufacturing variables, secondary emulsion droplet size and EE of peptide 
 
As shown in Table 4-2, the secondary emulsion droplet size in some emulsions was 
larger than the final particle size (Figure 3-4 B) indicating a significant shrinkage occurred after 
homogenization and in the in-liquid drying process. The correlation between the ratio of 
secondary emulsion droplet size/final particle size with secondary emulsion size was established 
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(Figure 4-10). The emulsions with large size appeared to shrink more than the smaller ones. 
However, this shrinkage did not significantly affect the EE of peptide. 
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Figure 4-10. Correlation between the ratio of secondary emulsion droplet size/final particle size with secondary emulsion size. 
 
 Conclusions 
The viscosity of primary emulsion increases when polymer concentration increases, or 
homogenization time decreases. The Sauter mean diameter of primary emulsion droplet size is 
proportional to the product of (Φଵ,  𝑊𝑒, 𝑅𝑒, 𝜔ଵ𝑡ଵ) with appropriate power index. A new 
dimensionless group (total surface energy/total energy input to fluid) was used to rationalize 
insertion of a proportionate time dependence in the scaling of the Sauter mean diameter. 
Increasing the viscosity of primary inhibits drug loss during microencapsulation while increasing 
droplet size enhances drug leakage to the outer water phase. The viscosity of secondary emulsion 
increases when dispersed phase fraction is increased or when homogenization time is decreased. 
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The Sauter mean diameter of secondary emulsion is proportional to the product of 
൬Φଶ,
ఓభᇲ
ఓ೎మ
, 𝜔ଶ𝑡ଶ൰ with each dimensionless group raised to appropriate power index. The final 
microspheres size is related to the secondary emulsion. The correlations identified in this study 
could be used in the further dimensional analysis.  
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 Nomenclature 
Symbols Definition Unit 
𝐶௣  polymer concentration mg/mL 
𝐷  rotor diameter m 
𝑑଴.ହ  volume median diameter m 
𝑑ଷ,ଶ  Sauter mean diameter m 
𝑁௣  particle number - 
𝑟ଷ,ଶ  Sauter mean radius m 
𝑃  power W 
𝑇ଵ  temperature of primary emulsion °C 
𝑇ଶ  temperature of secondary emulsion °C 
𝑡   homogenization time s 
𝑡ଵ  1st homogenization time s 
𝑡ଶ  2nd homogenization time s 
𝑉  volume of fluid mL 
𝑉௖  volume of continuous phase in primary emulsion mL 
𝑉′௖  volume of continuous phase in secondary emulsion mL 
𝑉ௗ  volume of disperse phase in primary emulsion mL 
𝑉′ௗ  volume of disperse phase in secondary emulsion mL 
   
   
Greek letters Definition Unit 
𝛾  surface energy J 
𝛿௄  Kolmogorov length scale of turbulence m 
ε  energy dissipation rate per unit mass of fluid J/kg 
𝜇  dynamic viscosity mPa·s 
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𝜇ଵ  viscosity of primary emulsion mPa·s 
𝜇′ଵ  viscosity of primary emulsion after cooling mPa·s 
𝜇ଶ  viscosity of secondary emulsion mPa·s 
𝜇௖భ   viscosity of continuous phase in primary emulsion mPa·s 
𝜇௖మ   viscosity of continuous phase in secondary emulsion mPa·s 
𝜇ௗ  viscosity of dispersed phase in primary emulsion mPa·s 
𝜌  liquid density kg·m−3 
𝜌௖  continuous phase density kg·m−3 
𝜌௖ଵ  polymer phase density kg·m
−3 
𝜌ௗ  dispersed phase density kg·m−3 
𝜎  interfacial tension (water/DCM) N/m 
𝜎′  interfacial tension (DCM/PVA) N/m 
Φଵ  dispersed phase volume fraction in primary emulsion - 
Φଶ  dispersed phase volume fraction in secondary emulsion - 
𝑣  kinematic viscosity m2/s 
𝑣௖  continuous phase kinematic viscosity m2/s 
𝜔  rotor speed s-1 
𝜔ଵ  1st homogenization speed s-1 
𝜔ଶ  2nd homogenization speed s-1 
   
Dimensionless 
group 
Definition Equation 
𝑃ை  Power number 𝑃ை =
௉
ఘఠయ஽ఱ
  
𝑅௘  Reynolds number 𝑅௘ =
ఘఠ஽మ
ఓ
  
𝑊௘  Weber number 𝑊௘ = 𝜌௖𝜔ଶ𝐷ଷ/σ  
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Chapter 5 Conclusions, Significance, and Future Directions
The work presented in this thesis begins to fill in the knowledge gap between raw 
materials/manufacturing parameters and product attributes/release performance/mechanisms in 
composition-equivalent PLGA microsphere formulations for controlled release of leuprolide. 
The knowledge gap was addressed by: 1) developing a series of composition-equivalent 
leuprolide/PLGA microsphere formulations, 2) developing correlates between the input 
variables, product attributes and release performance, 3) identifying the correlations between 
manufacturing variables with characteristics of emulsions. 
  In the reverse engineering of LD, we established comprehensive analytical methods for 
analyzing the specific components of the commercial product, identifying and quantifying the 
ingredients. The results are consistent with the values reported in the drug label and literature, 
and we found the leuprolide content by rigorous AAA and multiple extraction protocols to be 
slightly higher than listed in the drug label, although the difference is not statistically significant. 
The gelatin in LD appears to be Type B with Bloom 300. From the composition-equivalent 
formulations, we observe higher EE of gelatin (101 ± 1%) compared to the EE of leuprolide (42-
63%). The composition, Tg, and in vitro release kinetics of the microspheres loaded with 
leuprolide can be largely replicated on the bench scale. Changing manufacturing variables 
centered at a standard formulation does not strongly affect release behavior. Changes in initial 
burst release reflect changes in drug loading/encapsulation efficiency. The substitution of ring-
opening polymerized PLGA in place of polycondensation PLGA increases Tg and initial burst, 
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and slightly reduces long-term release rate and mass loss rate. The release mechanisms of 
standard condition formulation, Resomer formulation and LD appear to be the same and requires 
more than just mass loss to explain release. Indeed, the release may have a desorption 
component. Nondimensional correlations are established based on the literature, and the 
dimensionless Sauter mean diameter of primary emulsion droplet size is proportional to the 
product of dimensionless groups (Φଵ,  𝑊𝑒, 𝑅𝑒, 𝜔ଵ𝑡ଵ) raised to appropriate power indices. A new 
dimensionless group (total surface energy/total energy input to fluid) is used to rationalize 
insertion of a proportionate time dependence in the scaling of the Sauter mean diameter. The 
Sauter mean diameter of secondary emulsion is proportional to the product of dimensionless 
groups ൬Φଶ,
ఓᇱభ
ఓ೎మ
, 𝜔ଶ𝑡ଶ൰ raised to appropriate power indices. Increasing the viscosity of the 
primary emulsion inhibits drug loss during microencapsulation while increasing droplet size 
enhances drug leakage to the outer water phase.  
Future studies will determine the equivalence of composition-equivalent formulations to 
LD in vivo. This could be achieved by dosing selected formulations to rats subcutaneously and 
determining the pharmacokinetics of formulations for up to 35 days. The critical 
pharmacokinetic parameters, AUC0-t, AUC0-∞, Cmax and Tmax would be obtained to determine the 
bioequivalence. It may also be of interest to more definitively establish the dimensional analysis 
based on the correlations in Chapter 4. This could be achieved by expanding the range of 
variable values and involving confounding variables to prepare emulsions.  
This research has significant applications in the development of new and generic peptide 
loaded microsphere products. Particularly, the analytical methods that were developed in Chapter 
2 could be used to reverse engineer other peptide loaded microsphere commercial products. The 
effects identified in Chapter 3 could be used to optimize the manufacturing variables to prepare 
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formulations with desirable EE, particle size and release kinetics during pilot studies. The 
correlations established in Chapter 4 could be helpful to predict characteristics of emulsions and 
determine the initial values of parameter before experiments. The correlates in Chapter 3 and 4 
could greatly shorten development time and cost. These approaches may offer an aid in future 
FDA regulation development for generic drug of long acting release products. 
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